{"id":1471,"date":"2022-09-21T09:37:54","date_gmt":"2022-09-21T09:37:54","guid":{"rendered":"https:\/\/labolifeint.ditsmarketing.com\/publicaciones-cientificas\/"},"modified":"2023-02-28T10:40:20","modified_gmt":"2023-02-28T09:40:20","slug":"wissenschaftliche-publikationen","status":"publish","type":"page","link":"https:\/\/med.labolife.com\/de\/wissenschaftliche-publikationen\/","title":{"rendered":"Wissenschaftliche Publikationen"},"content":{"rendered":"<section class=\"l-section wpb_row height_small\"><div class=\"l-section-h i-cf\"><div class=\"g-cols vc_row via_flex valign_top type_default stacking_default\"><div class=\"vc_col-sm-12 wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"wpb_wrapper\"><h1 class=\"w-post-elm post_title entry-title color_link_inherit\">Wissenschaftliche Publikationen<\/h1><div class=\"w-separator size_small\"><\/div><div class=\"w-grid type_grid layout_2354\" id=\"us_grid_1\" data-filterable=\"true\"><style>#us_grid_1 .w-grid-item:not(:last-child){margin-bottom:3rem}#us_grid_1 .g-loadmore{margin-top:3rem}.layout_2354 .w-grid-item-h{}@media(max-width:634px){.layout_2354 .usg_hwrapper_2{display:none!important}}@media(min-width:636px){.layout_2354 .usg_hwrapper_3{display:none!important}}.layout_2354 .usg_post_custom_field_1{color:var(--color-alt-content-primary)!important;font-family:var(--font-h1)!important}.layout_2354 .usg_post_custom_field_2{color:var(--color-alt-content-primary)!important;font-family:var(--font-body)!important;font-style:italic!important}.layout_2354 .usg_post_content_1{text-align:justify!important}.layout_2354 .usg_vwrapper_1{padding-right:30px!important;border-right-width:3px!important;border-color:var(--color-content-border)!important;border-right-style:solid!important}.layout_2354 .usg_post_custom_field_3{color:var(--color-alt-content-primary)!important;font-family:var(--font-h1)!important}.layout_2354 .usg_post_custom_field_4{color:var(--color-alt-content-primary)!important;font-family:var(--font-body)!important;font-style:italic!important}.layout_2354 .usg_post_content_2{text-align:justify!important}.layout_2354 .usg_post_custom_field_5{color:var(--color-alt-content-primary)!important;font-family:var(--font-body)!important;font-style:italic!important}.layout_2354 .usg_post_custom_field_6{color:var(--color-alt-content-primary)!important;font-family:var(--font-body)!important;font-style:italic!important}@media (min-width:1025px) and (max-width:1280px){.layout_2354 .usg_vwrapper_1{padding-right:30px!important;border-right-width:3px!important;border-color:var(--color-content-border)!important;border-right-style:solid!important}}@media (min-width:601px) and (max-width:1024px){.layout_2354 .usg_vwrapper_1{border-color:var(--color-content-border)!important}}@media (max-width:600px){.layout_2354 .usg_vwrapper_1{border-color:var(--color-content-border)!important}.layout_2354 .usg_vwrapper_4{margin-top:20px!important}}<\/style><div class=\"w-grid-list\">\t<article class=\"w-grid-item size_1x1 post-5445 publicacion type-publicacion status-publish hentry category-publicaciones-cientificas-de\" data-id=\"5445\">\n\t\t<div class=\"w-grid-item-h\">\n\t\t\t\t\t\t<div class=\"w-hwrapper usg_hwrapper_2 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_1 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_1 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2025\/05\/life-15-00743.pdf\" target=\"_blank\" rel=\"noopener nofollow\">Active Substances from the Micro-Immunotherapy Medicine 2LMIREG Display Antioxidative Properties In Vitro in Two Colorectal Cancer Cell Lines<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_1 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_1 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">Life<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_2 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Garc\u00eda-Sureda, L., Jacques, C., Pons, D., Sastre-Serra, J., Oliver, J., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_5 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2025<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_1\"><p>Mitochondria play a crucial role in oxidative stress control and reactive oxygen species (ROS) generation, impacting many cellular processes. Dysregulated mitochondria are linked to diseases such as colorectal cancer (CRC), known for its aggressiveness. Since ROS plays a role in tumor growth and metastasis, there is considerable interest in developing therapies that target these reactives. This study investigates the effects of some active substances from the micro-immunotherapy (MI) medicine 2LMIREG<sup>\u00ae<\/sup> on mitochondrial metabolism parameters in two CRC-derived cell lines. HT-29 and the metastasis-derived SW620 cell lines, which heavily rely on ROS for proliferation, were used to evaluate the effects of the tested active substances. Cellular viability and various mitochondrial metabolism parameters were measured: ROS production, mitochondrial mass index, and mitochondrial DNA levels. In both cell lines, the tested MI formulation reduced cellular viability as well as ROS production compared to the vehicle used as a control. The treatment also appeared to increase the mitochondrial mass index without affecting mitochondrial DNA levels in the two CRC models. Altogether, these preliminary results report for the first time the mitochondria-related effects of some actives from 2LMIREG<sup>\u00ae<\/sup> in two CRC cell models and open perspectives for further in-depth metabolism-based studies.<\/p>\n<\/div><\/div><div class=\"w-vwrapper usg_vwrapper_2 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_1 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2025\/05\/life-15-00743.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_2 icon_atleft\" href=\"https:\/\/www.mdpi.com\/2075-1729\/15\/5\/743\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><div class=\"w-hwrapper usg_hwrapper_3 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_3 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_2 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2025\/05\/life-15-00743.pdf\" target=\"_blank\" rel=\"noopener nofollow\">Active Substances from the Micro-Immunotherapy Medicine 2LMIREG Display Antioxidative Properties In Vitro in Two Colorectal Cancer Cell Lines<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_4 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_3 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">Life<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_4 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Garc\u00eda-Sureda, L., Jacques, C., Pons, D., Sastre-Serra, J., Oliver, J., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_6 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2025<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_2 with_collapsible_content\" data-content-height=\"200px\"><div><p>Mitochondria play a crucial role in oxidative stress control and reactive oxygen species (ROS) generation, impacting many cellular processes. Dysregulated mitochondria are linked to diseases such as colorectal cancer (CRC), known for its aggressiveness. Since ROS plays a role in tumor growth and metastasis, there is considerable interest in developing therapies that target these reactives. This study investigates the effects of some active substances from the micro-immunotherapy (MI) medicine 2LMIREG<sup>\u00ae<\/sup> on mitochondrial metabolism parameters in two CRC-derived cell lines. HT-29 and the metastasis-derived SW620 cell lines, which heavily rely on ROS for proliferation, were used to evaluate the effects of the tested active substances. Cellular viability and various mitochondrial metabolism parameters were measured: ROS production, mitochondrial mass index, and mitochondrial DNA levels. In both cell lines, the tested MI formulation reduced cellular viability as well as ROS production compared to the vehicle used as a control. The treatment also appeared to increase the mitochondrial mass index without affecting mitochondrial DNA levels in the two CRC models. Altogether, these preliminary results report for the first time the mitochondria-related effects of some actives from 2LMIREG<sup>\u00ae<\/sup> in two CRC cell models and open perspectives for further in-depth metabolism-based studies.<\/p>\n<\/div><div class=\"toggle-links align_none\"><button class=\"collapsible-content-more\">Read more<\/button><button class=\"collapsible-content-less\">Show less<\/button><\/div><\/div><div class=\"w-vwrapper usg_vwrapper_4 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_3 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2025\/05\/life-15-00743.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_4 icon_atleft\" href=\"https:\/\/www.mdpi.com\/2075-1729\/15\/5\/743\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><\/div>\t\t<\/div>\n\t<\/article>\n\t<article class=\"w-grid-item size_1x1 post-5440 publicacion type-publicacion status-publish hentry category-publicaciones-cientificas-de\" data-id=\"5440\">\n\t\t<div class=\"w-grid-item-h\">\n\t\t\t\t\t\t<div class=\"w-hwrapper usg_hwrapper_2 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_1 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_1 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2025\/05\/ijms-26-04300.pdf\" target=\"_blank\" rel=\"noopener nofollow\">Active Substances from the Micro-Immunotherapy Medicine 2LC1\u00ae Show In Vitro Anti-Cancer Properties in Colon, Prostate, and Breast Cancer Models and Immune-Enhancing Capabilities in Human Macrophages<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_1 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_1 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">International Journal of Molecular Sciences<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_2 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Marchesi, I., Fiorentino F. P., Marchand, F., Chatelais, M., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_5 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2025<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_1\"><p>Tumor-associated macrophages (TAMs) play a pivotal role in cancer regulation by influencing tumor growth, metastasis, and the immune microenvironment. By providing low doses and ultra-low doses (ULD) of immune regulators to the organism, micro-immunotherapy (MI) medicines (MIM) could be seen as valuable adjuvant drugs in the context of a wide range of pathological conditions, including cancers. Thus, these MIM could target TAMs, affecting their phenotype and activities. In this study, the anti-tumor and the immune-stimulatory effects of four capsules out of the ten composing the Labo\u2019life\u2019s MIM 2LC1<sup>\u00ae<\/sup> (2LC1-1, 2LC1-6, 2LC1-7, and 2LC1-8), as well as the specific nucleic acid (SNA<sup>\u00ae<\/sup>) sequence SNA-MYC present at ULD in this medicine have been evaluated in vitro, in several cancer models, and in human monocyte-derived macrophages. Our results showed that the tested MI formulations increased the tumor cell death of spheroids from HCT-116 colon cancer cells, while reducing the spheroid volume. Moreover, the treatments impaired the clonogenic capabilities of two cancer cell lines from epithelial origin, the LNCaP prostate cancer and the MCF-7 breast cancer cells. Interestingly, ULD of the SNA-MYC shared similar anti-cancer capabilities in those models, and it led to a significant reduction in the expression of C-MYC when evaluated in a model of human M2 macrophages. In the same model, the MI formulations also increased the expression of CD86 and HLA-DR, two markers of M1 anti-tumor macrophages. In addition, the tested items modulated the secretion of a panel of chemokines related to macrophage activity and immune cell recruitment. Finally, our results showed that 2LC1-8 increased the phagocytosis capabilities of human monocyte-derived macrophages, thus possibly contributing to sustaining the immune functions of M1, which are crucial in the context of cancer. Even if more research is needed to uncover their exact mechanism of action, these results suggest that the tested capsules of 2LC1 as well as ULD of SNA-MYC display both anti-tumor and immune-enhancing effects.<\/p>\n<\/div><\/div><div class=\"w-vwrapper usg_vwrapper_2 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_1 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2025\/05\/ijms-26-04300.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_2 icon_atleft\" href=\"https:\/\/www.mdpi.com\/1422-0067\/26\/9\/4300\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><div class=\"w-hwrapper usg_hwrapper_3 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_3 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_2 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2025\/05\/ijms-26-04300.pdf\" target=\"_blank\" rel=\"noopener nofollow\">Active Substances from the Micro-Immunotherapy Medicine 2LC1\u00ae Show In Vitro Anti-Cancer Properties in Colon, Prostate, and Breast Cancer Models and Immune-Enhancing Capabilities in Human Macrophages<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_4 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_3 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">International Journal of Molecular Sciences<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_4 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Marchesi, I., Fiorentino F. P., Marchand, F., Chatelais, M., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_6 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2025<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_2 with_collapsible_content\" data-content-height=\"200px\"><div><p>Tumor-associated macrophages (TAMs) play a pivotal role in cancer regulation by influencing tumor growth, metastasis, and the immune microenvironment. By providing low doses and ultra-low doses (ULD) of immune regulators to the organism, micro-immunotherapy (MI) medicines (MIM) could be seen as valuable adjuvant drugs in the context of a wide range of pathological conditions, including cancers. Thus, these MIM could target TAMs, affecting their phenotype and activities. In this study, the anti-tumor and the immune-stimulatory effects of four capsules out of the ten composing the Labo\u2019life\u2019s MIM 2LC1<sup>\u00ae<\/sup> (2LC1-1, 2LC1-6, 2LC1-7, and 2LC1-8), as well as the specific nucleic acid (SNA<sup>\u00ae<\/sup>) sequence SNA-MYC present at ULD in this medicine have been evaluated in vitro, in several cancer models, and in human monocyte-derived macrophages. Our results showed that the tested MI formulations increased the tumor cell death of spheroids from HCT-116 colon cancer cells, while reducing the spheroid volume. Moreover, the treatments impaired the clonogenic capabilities of two cancer cell lines from epithelial origin, the LNCaP prostate cancer and the MCF-7 breast cancer cells. Interestingly, ULD of the SNA-MYC shared similar anti-cancer capabilities in those models, and it led to a significant reduction in the expression of C-MYC when evaluated in a model of human M2 macrophages. In the same model, the MI formulations also increased the expression of CD86 and HLA-DR, two markers of M1 anti-tumor macrophages. In addition, the tested items modulated the secretion of a panel of chemokines related to macrophage activity and immune cell recruitment. Finally, our results showed that 2LC1-8 increased the phagocytosis capabilities of human monocyte-derived macrophages, thus possibly contributing to sustaining the immune functions of M1, which are crucial in the context of cancer. Even if more research is needed to uncover their exact mechanism of action, these results suggest that the tested capsules of 2LC1 as well as ULD of SNA-MYC display both anti-tumor and immune-enhancing effects.<\/p>\n<\/div><div class=\"toggle-links align_none\"><button class=\"collapsible-content-more\">Read more<\/button><button class=\"collapsible-content-less\">Show less<\/button><\/div><\/div><div class=\"w-vwrapper usg_vwrapper_4 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_3 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2025\/05\/ijms-26-04300.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_4 icon_atleft\" href=\"https:\/\/www.mdpi.com\/1422-0067\/26\/9\/4300\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><\/div>\t\t<\/div>\n\t<\/article>\n\t<article class=\"w-grid-item size_1x1 post-5364 publicacion type-publicacion status-publish hentry category-publicaciones-cientificas-de\" data-id=\"5364\">\n\t\t<div class=\"w-grid-item-h\">\n\t\t\t\t\t\t<div class=\"w-hwrapper usg_hwrapper_2 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_1 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_1 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2025\/04\/JIR-498930-understanding-the-mode-of-action-of-several-active-ingredien.pdf\" target=\"_blank\" rel=\"noopener nofollow\">Understanding the Mode of Action of Several Active Ingredients from the Micro-Immunotherapy Medicine 2LZONA\u00ae<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_1 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_1 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">Journal of Inflammation Research<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_2 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Marchand, F., Chatelais, M., Brulefert, A., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_5 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2025<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_1\"><p><strong>Introduction:<\/strong> Varicella-zoster virus (VZV) affects over 90% of the global population. The initial encounter with VZV, often in the early years of childhood, results in varicella. From latency, VZV can reactivate in later stages of life, leading to the development of herpes zoster. Considering the importance of host immune responses in preventing reactivation and clinical manifestations associated with VZV infection, a therapy that sustains the immune system could be of great interest.<\/p>\n<p><strong>Objective:<\/strong> The present work aimed to set the basis of the possible mode of action of 2LZONA<sup>\u00ae<\/sup>, a micro-immunotherapy medicine composed of five different capsules. Thus, the effects of several active substances employed in this medicine were assessed in human primary immune-related cells.<\/p>\n<p><strong>Results and Discussion:<\/strong> Our results showed that DNA (8 CH) and RNA (8 CH), two active substances used in 2LZONA, displayed phagocytosis-enhancing capabilities in granulocytes and contained sub-micron particles that could explain, at least partially, the observed effect. These two active substances tested singularly and together with other actives of 2LZONA\u2019s capsules, modulated the proliferation of immature, transitory, and mature subsets of natural killer (NK) cells in an IL-15-like pattern, suggesting an enhancement of their activation levels. Moreover, the tested items of 2LZONA increased the secretion of IL-2, IL-6, IL-13, and TNF-\u03b1 in human peripheral blood mononuclear cells (PBMCs). Furthermore, the proliferation of PBMCs-derived NK cells, intermediate monocytes, and neutrophils was slightly increased by this treatment. In CD3 and CD3\/CD28 pre-primed conditions, actives present in one capsule of 2LZONA enhanced the secretion of IL-6 and TNF-\u03b1. Finally, one capsule of 2LZONA reduced the expression of human leukocyte antigen (HLA) in IFN-inflamed endothelial cells. Overall, these data provide, for the first time, preliminary experimental evidence of the mechanisms of action of some of the active ingredients employed in 2LZONA capsules.<\/p>\n<\/div><\/div><div class=\"w-vwrapper usg_vwrapper_2 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_1 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2025\/04\/JIR-498930-understanding-the-mode-of-action-of-several-active-ingredien.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_2 icon_atleft\" href=\"https:\/\/www.dovepress.com\/articles.php?article_id=101373\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><div class=\"w-hwrapper usg_hwrapper_3 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_3 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_2 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2025\/04\/JIR-498930-understanding-the-mode-of-action-of-several-active-ingredien.pdf\" target=\"_blank\" rel=\"noopener nofollow\">Understanding the Mode of Action of Several Active Ingredients from the Micro-Immunotherapy Medicine 2LZONA\u00ae<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_4 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_3 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">Journal of Inflammation Research<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_4 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Marchand, F., Chatelais, M., Brulefert, A., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_6 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2025<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_2 with_collapsible_content\" data-content-height=\"200px\"><div><p><strong>Introduction:<\/strong> Varicella-zoster virus (VZV) affects over 90% of the global population. The initial encounter with VZV, often in the early years of childhood, results in varicella. From latency, VZV can reactivate in later stages of life, leading to the development of herpes zoster. Considering the importance of host immune responses in preventing reactivation and clinical manifestations associated with VZV infection, a therapy that sustains the immune system could be of great interest.<\/p>\n<p><strong>Objective:<\/strong> The present work aimed to set the basis of the possible mode of action of 2LZONA<sup>\u00ae<\/sup>, a micro-immunotherapy medicine composed of five different capsules. Thus, the effects of several active substances employed in this medicine were assessed in human primary immune-related cells.<\/p>\n<p><strong>Results and Discussion:<\/strong> Our results showed that DNA (8 CH) and RNA (8 CH), two active substances used in 2LZONA, displayed phagocytosis-enhancing capabilities in granulocytes and contained sub-micron particles that could explain, at least partially, the observed effect. These two active substances tested singularly and together with other actives of 2LZONA\u2019s capsules, modulated the proliferation of immature, transitory, and mature subsets of natural killer (NK) cells in an IL-15-like pattern, suggesting an enhancement of their activation levels. Moreover, the tested items of 2LZONA increased the secretion of IL-2, IL-6, IL-13, and TNF-\u03b1 in human peripheral blood mononuclear cells (PBMCs). Furthermore, the proliferation of PBMCs-derived NK cells, intermediate monocytes, and neutrophils was slightly increased by this treatment. In CD3 and CD3\/CD28 pre-primed conditions, actives present in one capsule of 2LZONA enhanced the secretion of IL-6 and TNF-\u03b1. Finally, one capsule of 2LZONA reduced the expression of human leukocyte antigen (HLA) in IFN-inflamed endothelial cells. Overall, these data provide, for the first time, preliminary experimental evidence of the mechanisms of action of some of the active ingredients employed in 2LZONA capsules.<\/p>\n<\/div><div class=\"toggle-links align_none\"><button class=\"collapsible-content-more\">Read more<\/button><button class=\"collapsible-content-less\">Show less<\/button><\/div><\/div><div class=\"w-vwrapper usg_vwrapper_4 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_3 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2025\/04\/JIR-498930-understanding-the-mode-of-action-of-several-active-ingredien.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_4 icon_atleft\" href=\"https:\/\/www.dovepress.com\/articles.php?article_id=101373\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><\/div>\t\t<\/div>\n\t<\/article>\n\t<article class=\"w-grid-item size_1x1 post-4804 publicacion type-publicacion status-publish hentry category-publicaciones-cientificas-de\" data-id=\"4804\">\n\t\t<div class=\"w-grid-item-h\">\n\t\t\t\t\t\t<div class=\"w-hwrapper usg_hwrapper_2 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_1 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_1 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2024\/10\/life-14-00552.pdf\" target=\"_blank\" rel=\"noopener nofollow\">Exploring the Potential of Micro-Immunotherapy in the Treatment of Periodontitis<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_1 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_1 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">Life<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_2 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Ferr\u00e0-Ca\u00f1ellas, MDM., Garcia-Sureda, L.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_5 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2024<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_1\"><p>Periodontitis, characterized by the progressive destruction of dental support tissues due to altered immune responses, poses a significant concern for public health. This condition involves intricate interactions between the immune response and oral microbiome, where innate and adaptive immune responses, with their diverse cell populations and inflammatory mediators, play crucial roles in this immunopathology. Indeed, cytokines, chemokines, growth factors, and immune cells perform key functions in tissue remodeling. Focusing on periodontal therapies, our attention turns to micro-immunotherapy (MI), employing low doses (LDs) and ultra-low doses (ULDs) of immunological signaling molecules like cytokines, growth factors, and hormones. Existing studies across various fields lay the groundwork for the application of MI in periodontitis, highlighting its anti-inflammatory and regenerative potential in soft tissue models based on in vitro research. In summary, this review underscores the versatility and potential of MI in managing periodontal health, urging further investigations to solidify its clinical integration. MI supports an innovative approach by modulating immune responses at low doses to address periodontitis.<\/p>\n<\/div><\/div><div class=\"w-vwrapper usg_vwrapper_2 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_1 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2024\/10\/life-14-00552.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_2 icon_atleft\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11122531\/\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><div class=\"w-hwrapper usg_hwrapper_3 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_3 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_2 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2024\/10\/life-14-00552.pdf\" target=\"_blank\" rel=\"noopener nofollow\">Exploring the Potential of Micro-Immunotherapy in the Treatment of Periodontitis<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_4 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_3 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">Life<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_4 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Ferr\u00e0-Ca\u00f1ellas, MDM., Garcia-Sureda, L.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_6 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2024<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_2 with_collapsible_content\" data-content-height=\"200px\"><div><p>Periodontitis, characterized by the progressive destruction of dental support tissues due to altered immune responses, poses a significant concern for public health. This condition involves intricate interactions between the immune response and oral microbiome, where innate and adaptive immune responses, with their diverse cell populations and inflammatory mediators, play crucial roles in this immunopathology. Indeed, cytokines, chemokines, growth factors, and immune cells perform key functions in tissue remodeling. Focusing on periodontal therapies, our attention turns to micro-immunotherapy (MI), employing low doses (LDs) and ultra-low doses (ULDs) of immunological signaling molecules like cytokines, growth factors, and hormones. Existing studies across various fields lay the groundwork for the application of MI in periodontitis, highlighting its anti-inflammatory and regenerative potential in soft tissue models based on in vitro research. In summary, this review underscores the versatility and potential of MI in managing periodontal health, urging further investigations to solidify its clinical integration. MI supports an innovative approach by modulating immune responses at low doses to address periodontitis.<\/p>\n<\/div><div class=\"toggle-links align_none\"><button class=\"collapsible-content-more\">Read more<\/button><button class=\"collapsible-content-less\">Show less<\/button><\/div><\/div><div class=\"w-vwrapper usg_vwrapper_4 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_3 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2024\/10\/life-14-00552.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_4 icon_atleft\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11122531\/\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><\/div>\t\t<\/div>\n\t<\/article>\n\t<article class=\"w-grid-item size_1x1 post-4796 publicacion type-publicacion status-publish hentry category-publicaciones-cientificas-de\" data-id=\"4796\">\n\t\t<div class=\"w-grid-item-h\">\n\t\t\t\t\t\t<div class=\"w-hwrapper usg_hwrapper_2 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_1 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_1 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2024\/10\/life-14-00375-v2.pdf\" target=\"_blank\" rel=\"noopener nofollow\">In Vitro Study of Interleukin-6 when Used at Low Dose and Ultra-Low Dose in Micro-Immunotherapy<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_1 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_1 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">Life<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_2 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Marchand, F., Chatelais, M., Brulefert, A., Riffault, M., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_5 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2024<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_1\"><p>As one of the major cytokines implicated in the orchestration of immune responses, interleukin 6 (IL-6) can either act as a pro- or an anti-inflammatory factor, depending on the micro-environment. In micro-immunotherapy (MI) medicines, IL-6 is employed at low doses (LD) and ultra-low doses (ULD), expressed in centesimal Hahnemannian (CH), and used alone or in combination with other immune regulators to modulate patients\u2019 immune responses. The present study focused on assessing the in vitro immune-modulatory effects of two IL-6-containing MI products: (i) the unitary IL-6 (4 CH) and (ii) the complex MI-medicine (MIM) 2LALERG<sup>\u00ae<\/sup>, which includes IL-6 (17 CH) in association with other actives in its formulation. Our results showed that IL-6 (4 CH) activated granulocytes under basal conditions, and natural killer cells in the presence of an anti-CD3 signal, as assessed by their CD69 expression. In addition, IL-6 (4 CH) balanced the macrophages\u2019 differentiation toward a M2a profile. On the other hand, the tested 2LALERG<sup>\u00ae<\/sup> capsule inhibited the histamine degranulation of rats\u2019 peritoneal mast cells and reduced the release of IL-6 itself in inflamed human macrophages. Altogether, these data provide novel pieces of evidence on the double-edged potential of the LD and ULD of IL-6 in immune responses modulation, when employed in MI.<\/p>\n<\/div><\/div><div class=\"w-vwrapper usg_vwrapper_2 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_1 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2024\/10\/life-14-00375-v2.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_2 icon_atleft\" href=\"https:\/\/www.mdpi.com\/2075-1729\/14\/3\/375\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><div class=\"w-hwrapper usg_hwrapper_3 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_3 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_2 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2024\/10\/life-14-00375-v2.pdf\" target=\"_blank\" rel=\"noopener nofollow\">In Vitro Study of Interleukin-6 when Used at Low Dose and Ultra-Low Dose in Micro-Immunotherapy<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_4 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_3 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">Life<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_4 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Marchand, F., Chatelais, M., Brulefert, A., Riffault, M., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_6 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2024<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_2 with_collapsible_content\" data-content-height=\"200px\"><div><p>As one of the major cytokines implicated in the orchestration of immune responses, interleukin 6 (IL-6) can either act as a pro- or an anti-inflammatory factor, depending on the micro-environment. In micro-immunotherapy (MI) medicines, IL-6 is employed at low doses (LD) and ultra-low doses (ULD), expressed in centesimal Hahnemannian (CH), and used alone or in combination with other immune regulators to modulate patients\u2019 immune responses. The present study focused on assessing the in vitro immune-modulatory effects of two IL-6-containing MI products: (i) the unitary IL-6 (4 CH) and (ii) the complex MI-medicine (MIM) 2LALERG<sup>\u00ae<\/sup>, which includes IL-6 (17 CH) in association with other actives in its formulation. Our results showed that IL-6 (4 CH) activated granulocytes under basal conditions, and natural killer cells in the presence of an anti-CD3 signal, as assessed by their CD69 expression. In addition, IL-6 (4 CH) balanced the macrophages\u2019 differentiation toward a M2a profile. On the other hand, the tested 2LALERG<sup>\u00ae<\/sup> capsule inhibited the histamine degranulation of rats\u2019 peritoneal mast cells and reduced the release of IL-6 itself in inflamed human macrophages. Altogether, these data provide novel pieces of evidence on the double-edged potential of the LD and ULD of IL-6 in immune responses modulation, when employed in MI.<\/p>\n<\/div><div class=\"toggle-links align_none\"><button class=\"collapsible-content-more\">Read more<\/button><button class=\"collapsible-content-less\">Show less<\/button><\/div><\/div><div class=\"w-vwrapper usg_vwrapper_4 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_3 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2024\/10\/life-14-00375-v2.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_4 icon_atleft\" href=\"https:\/\/www.mdpi.com\/2075-1729\/14\/3\/375\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><\/div>\t\t<\/div>\n\t<\/article>\n\t<article class=\"w-grid-item size_1x1 post-4253 publicacion type-publicacion status-publish hentry category-publicaciones-cientificas-de\" data-id=\"4253\">\n\t\t<div class=\"w-grid-item-h\">\n\t\t\t\t\t\t<div class=\"w-hwrapper usg_hwrapper_2 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_1 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_1 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2024\/04\/cancers-16-01421-v2.pdf\" target=\"_blank\" rel=\"noopener nofollow\">The Micro-Immunotherapy Medicine 2LPAPI\u00ae Displays Immune-Modulatory Effects in a Model of Human Papillomavirus Type-16 L1-Protein Capsid-Treated Human Peripheral Blood Mononuclear Cells and Antiproliferative Effects in a Model of Cervical Cancer Cells<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_1 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_1 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">Cancers<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_2 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Marchand, F. Chatelais, M., Albinet, V., Coustal, C., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_5 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2024<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_1\"><p><strong>Simple Summary: <\/strong>The human papillomavirus (HPV), a major carcinogenic pathogen, can cause cervical cancer through persistent infection. The immune system typically fights off the virus, albeit long-term activation may promote carcinogenesis. The micro-immunotherapy medicine 2LPAPI<sup>\u00ae<\/sup> holds promise for aiding viral clearance and mitigating cervical cancer risk, and our research aimed to examine the effects of this medicine in vitro. We focused our investigations on the two most prevalent genotypes of HPV causing persistent infection, HPV-16 and HPV-18. We found that 2LPAPI<sup>\u00ae<\/sup>boosted the secretion of IL-6, IFN-\u03b3, and IP-10 in human immune cells when exposed to HPV-16 proteins, suggesting enhanced defensive responses to HPV-16. Some of the active substances curtailed T-cell proliferation and activity and displayed antiproliferative properties on HPV-18 positive cervical cancer-derived HeLa cells in nutrient-restricted conditions. These results unveil 2LPAPI<sup>\u00ae<\/sup>\u2019s potential dual role: immunomodulation for HPV-16-affected immune cells and antiproliferative activity against a model of HPV-18-positive-cervical cancer cells.<\/p>\n<p><strong>Abstract: <\/strong>Human papillomavirus (HPV) is the second most common infectious agent causing cancer. Persistent infection with high-risk (HR)-HPV can lead to cervical intra-epithelial neoplasia and cervical carcinomas (CC). While host immune response is necessary for viral clearance, chronic immune activation contributes to a low-grade inflammation that can ultimately lead to carcinogenesis. The micro-immunotherapy medicine (MIM) 2LPAPI<sup>\u00ae<\/sup> could be a valuable tool to manage the clearance of the virus and reduce the risk of developing CC. In this in vitro study, we aimed to investigate its mode of action. We showed that actives from the MIM increased the IL-6, IFN-\u03b3, and IP-10 secretion in human peripheral blood mononuclear cells (PBMCs) exposed to peptides derived from the HPV-16 capsid (HPV16<sub>(L1)<\/sub>). This could reflect an increase in the immune activity toward HPV-16. At the same time, some active substances reduced the lympho-proliferation and the expression of T-cell activation markers. Finally, some of the MIM actives displayed antiproliferative effects in CC-derived HeLa cells under serum-starvation conditions. Altogether, this body of data highlighted for the first time the dual effect of MIM in the framework of HR-HPV infections as a potential (i) immune modulator of HPV16<sub>(L1)<\/sub>-treated PBMCs and (ii) antiproliferative agent of HPV-positive CC cells.<\/p>\n<\/div><\/div><div class=\"w-vwrapper usg_vwrapper_2 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_1 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2024\/04\/cancers-16-01421-v2.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_2 icon_atleft\" href=\"https:\/\/www.mdpi.com\/2072-6694\/16\/7\/1421\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><div class=\"w-hwrapper usg_hwrapper_3 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_3 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_2 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2024\/04\/cancers-16-01421-v2.pdf\" target=\"_blank\" rel=\"noopener nofollow\">The Micro-Immunotherapy Medicine 2LPAPI\u00ae Displays Immune-Modulatory Effects in a Model of Human Papillomavirus Type-16 L1-Protein Capsid-Treated Human Peripheral Blood Mononuclear Cells and Antiproliferative Effects in a Model of Cervical Cancer Cells<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_4 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_3 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">Cancers<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_4 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Marchand, F. Chatelais, M., Albinet, V., Coustal, C., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_6 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2024<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_2 with_collapsible_content\" data-content-height=\"200px\"><div><p><strong>Simple Summary: <\/strong>The human papillomavirus (HPV), a major carcinogenic pathogen, can cause cervical cancer through persistent infection. The immune system typically fights off the virus, albeit long-term activation may promote carcinogenesis. The micro-immunotherapy medicine 2LPAPI<sup>\u00ae<\/sup> holds promise for aiding viral clearance and mitigating cervical cancer risk, and our research aimed to examine the effects of this medicine in vitro. We focused our investigations on the two most prevalent genotypes of HPV causing persistent infection, HPV-16 and HPV-18. We found that 2LPAPI<sup>\u00ae<\/sup>boosted the secretion of IL-6, IFN-\u03b3, and IP-10 in human immune cells when exposed to HPV-16 proteins, suggesting enhanced defensive responses to HPV-16. Some of the active substances curtailed T-cell proliferation and activity and displayed antiproliferative properties on HPV-18 positive cervical cancer-derived HeLa cells in nutrient-restricted conditions. These results unveil 2LPAPI<sup>\u00ae<\/sup>\u2019s potential dual role: immunomodulation for HPV-16-affected immune cells and antiproliferative activity against a model of HPV-18-positive-cervical cancer cells.<\/p>\n<p><strong>Abstract: <\/strong>Human papillomavirus (HPV) is the second most common infectious agent causing cancer. Persistent infection with high-risk (HR)-HPV can lead to cervical intra-epithelial neoplasia and cervical carcinomas (CC). While host immune response is necessary for viral clearance, chronic immune activation contributes to a low-grade inflammation that can ultimately lead to carcinogenesis. The micro-immunotherapy medicine (MIM) 2LPAPI<sup>\u00ae<\/sup> could be a valuable tool to manage the clearance of the virus and reduce the risk of developing CC. In this in vitro study, we aimed to investigate its mode of action. We showed that actives from the MIM increased the IL-6, IFN-\u03b3, and IP-10 secretion in human peripheral blood mononuclear cells (PBMCs) exposed to peptides derived from the HPV-16 capsid (HPV16<sub>(L1)<\/sub>). This could reflect an increase in the immune activity toward HPV-16. At the same time, some active substances reduced the lympho-proliferation and the expression of T-cell activation markers. Finally, some of the MIM actives displayed antiproliferative effects in CC-derived HeLa cells under serum-starvation conditions. Altogether, this body of data highlighted for the first time the dual effect of MIM in the framework of HR-HPV infections as a potential (i) immune modulator of HPV16<sub>(L1)<\/sub>-treated PBMCs and (ii) antiproliferative agent of HPV-positive CC cells.<\/p>\n<\/div><div class=\"toggle-links align_none\"><button class=\"collapsible-content-more\">Read more<\/button><button class=\"collapsible-content-less\">Show less<\/button><\/div><\/div><div class=\"w-vwrapper usg_vwrapper_4 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_3 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2024\/04\/cancers-16-01421-v2.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_4 icon_atleft\" href=\"https:\/\/www.mdpi.com\/2072-6694\/16\/7\/1421\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><\/div>\t\t<\/div>\n\t<\/article>\n\t<article class=\"w-grid-item size_1x1 post-4173 publicacion type-publicacion status-publish hentry category-publicaciones-cientificas-de\" data-id=\"4173\">\n\t\t<div class=\"w-grid-item-h\">\n\t\t\t\t\t\t<div class=\"w-hwrapper usg_hwrapper_2 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_1 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_1 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2024\/02\/JIR-445053-actives-from-the-micro-immunotherapy-medicine-2lmireg-reg-r.pdf\" target=\"_blank\" rel=\"noopener nofollow\">Actives from the Micro-Immunotherapy Medicine 2LMIREG\u00ae Reduce the Expression of Cytokines and Immune-Related Markers Including Interleukin-2 and HLA-II While Modulating Oxidative Stress and Mitochondrial Function<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_1 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_1 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">Journal of Inflammation Research<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_2 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Marchand, F., Chatelais, M., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_5 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2024<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_1\"><p><strong>Introduction:<\/strong> Micro-immunotherapy (MI) is a therapeutic option employing low doses (LD) and ultra-low doses (ULD) of cytokines and immune factors to help the organism at modulating the immune responses. In an overpowering inflammatory context, this strategy may support the restoration of the body\u2019s homeostasis, as the active ingredients of MI medicines\u2019 (MIM) could boost or slow down the physiological functions of the immune cells. The aim of the study is to evaluate for the first time the in vitro anti-inflammatory properties of some actives employed by the MIM of interest in several human immune cell models.<\/p>\n<p><strong>Methods:<\/strong> In the first part of the study, the effects of the actives from the MIM of interest were assessed from a molecular standpoint: the expression of HLA-II, interleukin (IL)-2, and the secretion of several other cytokines were evaluated. In addition, as mitochondrial metabolism is also involved in the inflammatory processes, the second part of the study aimed at assessing the effects of these actives on the mitochondrial reactive oxygen species (ROS) production and on the mitochondrial membrane potential.<\/p>\n<p><strong>Results:<\/strong> We showed that the tested actives decreased the expression of HLA-DR and HLA-DP in IFN-\u03b3-stimulated endothelial cells and in LPS-treated-M1-macrophages. The tested MIM slightly reduced the intracellular expression of IL-2 in CD4<sup>+<\/sup> and CD8<sup>+<\/sup> T-cells isolated from PMA\/Iono-stimulated human PBMCs. Additionally, while the secretion of IL-2, IL-10, and IFN-\u03b3 was diminished, the treatment increased IL-6, IL-9, and IL-17A, which may correspond to a \u201cTh17-like\u201d secretory pattern. Interestingly, in PMA\/Iono-treated PBMCs, we reported that the treatment reduced the ROS production in B-cells. Finally, in PMA\/Iono-treated human macrophages, we showed that the treatment slightly protected the cells from early cell death\/apoptosis.<\/p>\n<p><strong>Discussion:<\/strong> Overall, these results provide data about the molecular and functional anti-inflammatory effects of several actives contained in the tested MIM in immune-related cells, and their impact on two mitochondria-related processes.<\/p>\n<p><strong>Keywords:<\/strong> micro-immunotherapy, mitochondrial metabolism, cytokines, inflammation, anti-inflammatory, interleukin-2<\/p>\n<\/div><\/div><div class=\"w-vwrapper usg_vwrapper_2 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_1 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2024\/02\/JIR-445053-actives-from-the-micro-immunotherapy-medicine-2lmireg-reg-r.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_2 icon_atleft\" href=\"https:\/\/www.dovepress.com\/articles.php?article_id=90613\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><div class=\"w-hwrapper usg_hwrapper_3 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_3 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_2 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2024\/02\/JIR-445053-actives-from-the-micro-immunotherapy-medicine-2lmireg-reg-r.pdf\" target=\"_blank\" rel=\"noopener nofollow\">Actives from the Micro-Immunotherapy Medicine 2LMIREG\u00ae Reduce the Expression of Cytokines and Immune-Related Markers Including Interleukin-2 and HLA-II While Modulating Oxidative Stress and Mitochondrial Function<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_4 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_3 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">Journal of Inflammation Research<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_4 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Marchand, F., Chatelais, M., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_6 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2024<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_2 with_collapsible_content\" data-content-height=\"200px\"><div><p><strong>Introduction:<\/strong> Micro-immunotherapy (MI) is a therapeutic option employing low doses (LD) and ultra-low doses (ULD) of cytokines and immune factors to help the organism at modulating the immune responses. In an overpowering inflammatory context, this strategy may support the restoration of the body\u2019s homeostasis, as the active ingredients of MI medicines\u2019 (MIM) could boost or slow down the physiological functions of the immune cells. The aim of the study is to evaluate for the first time the in vitro anti-inflammatory properties of some actives employed by the MIM of interest in several human immune cell models.<\/p>\n<p><strong>Methods:<\/strong> In the first part of the study, the effects of the actives from the MIM of interest were assessed from a molecular standpoint: the expression of HLA-II, interleukin (IL)-2, and the secretion of several other cytokines were evaluated. In addition, as mitochondrial metabolism is also involved in the inflammatory processes, the second part of the study aimed at assessing the effects of these actives on the mitochondrial reactive oxygen species (ROS) production and on the mitochondrial membrane potential.<\/p>\n<p><strong>Results:<\/strong> We showed that the tested actives decreased the expression of HLA-DR and HLA-DP in IFN-\u03b3-stimulated endothelial cells and in LPS-treated-M1-macrophages. The tested MIM slightly reduced the intracellular expression of IL-2 in CD4<sup>+<\/sup> and CD8<sup>+<\/sup> T-cells isolated from PMA\/Iono-stimulated human PBMCs. Additionally, while the secretion of IL-2, IL-10, and IFN-\u03b3 was diminished, the treatment increased IL-6, IL-9, and IL-17A, which may correspond to a \u201cTh17-like\u201d secretory pattern. Interestingly, in PMA\/Iono-treated PBMCs, we reported that the treatment reduced the ROS production in B-cells. Finally, in PMA\/Iono-treated human macrophages, we showed that the treatment slightly protected the cells from early cell death\/apoptosis.<\/p>\n<p><strong>Discussion:<\/strong> Overall, these results provide data about the molecular and functional anti-inflammatory effects of several actives contained in the tested MIM in immune-related cells, and their impact on two mitochondria-related processes.<\/p>\n<p><strong>Keywords:<\/strong> micro-immunotherapy, mitochondrial metabolism, cytokines, inflammation, anti-inflammatory, interleukin-2<\/p>\n<\/div><div class=\"toggle-links align_none\"><button class=\"collapsible-content-more\">Read more<\/button><button class=\"collapsible-content-less\">Show less<\/button><\/div><\/div><div class=\"w-vwrapper usg_vwrapper_4 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_3 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2024\/02\/JIR-445053-actives-from-the-micro-immunotherapy-medicine-2lmireg-reg-r.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_4 icon_atleft\" href=\"https:\/\/www.dovepress.com\/articles.php?article_id=90613\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><\/div>\t\t<\/div>\n\t<\/article>\n\t<article class=\"w-grid-item size_1x1 post-3981 publicacion type-publicacion status-publish hentry category-publicaciones-cientificas-de\" data-id=\"3981\">\n\t\t<div class=\"w-grid-item-h\">\n\t\t\t\t\t\t<div class=\"w-hwrapper usg_hwrapper_2 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_1 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_1 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2024\/01\/life-14-00102.pdf\" target=\"_blank\" rel=\"noopener nofollow\">Understanding the Mode of Action of a Micro-Immunotherapy Formulation: Pre-Clinical Evidence from the Study of 2LEBV\u00ae Active Ingredients<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_1 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_1 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">Life<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_2 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Marchand, F., Chatelais, M., Brulefert, A., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_5 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2024<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_1\"><p style=\"text-align: justify;\">Background: Epstein\u2013Barr virus (EBV) is often kept silent and asymptomatic; however, its reactivation induces a chronic and\/or recurrent infection that is associated with numerous diseases, including cancer and inflammation-related disorders. As no specific treatment is currently available, the immune factors-based micro-immunotherapy (MI) medicine 2LEBV<sup>\u00ae<\/sup> could be considered a valuable therapeutic option to sustain the immune system in EBV reactivation. Methods: The present work aimed to investigate, for the first time, the effect of 2LEBV<sup>\u00ae<\/sup> in several in vitro models of uninfected immune-related cells. Results: 2LEBV<sup>\u00ae<\/sup> displayed phagocytosis-enhancing capabilities in granulocytes. In human peripheral blood mononuclear cells (PBMCs), it increased the intra- and extra-cellular expression of interleukin (IL)-2. Moreover, it modulated the secretion of other cytokines, increasing IL-4, IL-6, and tumor necrosis factor-\u03b1 levels or lowering other cytokines levels such as IL-9. Finally, 2LEBV<sup>\u00ae<\/sup> reduced the expression of human leukocyte antigen (HLA)-II in endothelial cells and macrophages. Conclusions: Although these data are still preliminary and the chosen models do not consider the underlying EBV-reactivation mechanisms, they still provide a better understanding of the mechanisms of action of 2LEBV<sup>\u00ae<\/sup>, both at functional and molecular levels. Furthermore, they open perspectives regarding the potential targets of 2LEBV<sup>\u00ae<\/sup> in its employment as a therapeutic intervention for EBV-associated diseases.<\/p>\n<\/div><\/div><div class=\"w-vwrapper usg_vwrapper_2 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_1 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2024\/01\/life-14-00102.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_2 icon_atleft\" href=\"https:\/\/www.mdpi.com\/2075-1729\/14\/1\/102\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><div class=\"w-hwrapper usg_hwrapper_3 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_3 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_2 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2024\/01\/life-14-00102.pdf\" target=\"_blank\" rel=\"noopener nofollow\">Understanding the Mode of Action of a Micro-Immunotherapy Formulation: Pre-Clinical Evidence from the Study of 2LEBV\u00ae Active Ingredients<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_4 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_3 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">Life<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_4 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Marchand, F., Chatelais, M., Brulefert, A., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_6 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2024<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_2 with_collapsible_content\" data-content-height=\"200px\"><div><p style=\"text-align: justify;\">Background: Epstein\u2013Barr virus (EBV) is often kept silent and asymptomatic; however, its reactivation induces a chronic and\/or recurrent infection that is associated with numerous diseases, including cancer and inflammation-related disorders. As no specific treatment is currently available, the immune factors-based micro-immunotherapy (MI) medicine 2LEBV<sup>\u00ae<\/sup> could be considered a valuable therapeutic option to sustain the immune system in EBV reactivation. Methods: The present work aimed to investigate, for the first time, the effect of 2LEBV<sup>\u00ae<\/sup> in several in vitro models of uninfected immune-related cells. Results: 2LEBV<sup>\u00ae<\/sup> displayed phagocytosis-enhancing capabilities in granulocytes. In human peripheral blood mononuclear cells (PBMCs), it increased the intra- and extra-cellular expression of interleukin (IL)-2. Moreover, it modulated the secretion of other cytokines, increasing IL-4, IL-6, and tumor necrosis factor-\u03b1 levels or lowering other cytokines levels such as IL-9. Finally, 2LEBV<sup>\u00ae<\/sup> reduced the expression of human leukocyte antigen (HLA)-II in endothelial cells and macrophages. Conclusions: Although these data are still preliminary and the chosen models do not consider the underlying EBV-reactivation mechanisms, they still provide a better understanding of the mechanisms of action of 2LEBV<sup>\u00ae<\/sup>, both at functional and molecular levels. Furthermore, they open perspectives regarding the potential targets of 2LEBV<sup>\u00ae<\/sup> in its employment as a therapeutic intervention for EBV-associated diseases.<\/p>\n<\/div><div class=\"toggle-links align_none\"><button class=\"collapsible-content-more\">Read more<\/button><button class=\"collapsible-content-less\">Show less<\/button><\/div><\/div><div class=\"w-vwrapper usg_vwrapper_4 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_3 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2024\/01\/life-14-00102.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_4 icon_atleft\" href=\"https:\/\/www.mdpi.com\/2075-1729\/14\/1\/102\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><\/div>\t\t<\/div>\n\t<\/article>\n\t<article class=\"w-grid-item size_1x1 post-3687 publicacion type-publicacion status-publish hentry category-publicaciones-cientificas-de\" data-id=\"3687\">\n\t\t<div class=\"w-grid-item-h\">\n\t\t\t\t\t\t<div class=\"w-hwrapper usg_hwrapper_2 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_1 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_1 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/06\/ijms-24-10484.pdf\" target=\"_blank\" rel=\"noopener nofollow\">A Sequential Micro-Immunotherapy Medicine Increases Collagen Deposition in Human Gingival Fibroblasts and in an Engineered 3D Gingival Model under Inflammatory Conditions<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_1 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_1 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">International Journal of Molecular Sciences<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_2 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Ferr\u00e0, M., Munar, M., Floris, I., Ramis, J.M., Monjo, M., Garc\u00eda, L.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_5 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2023<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_1\"><p style=\"text-align: justify;\">Periodontal therapies use immune mediators, but their side effects can increase with dosage. Micro-immunotherapy (MI) is a promising alternative that employs immune regulators at low and ultralow doses to minimize adverse effects. In this study, the effects of 5 capsules and the entire 10-capsule sequence of the sequential MI medicine (MIM-seq) were tested in two in vitro models of periodontitis. Firstly, human gingival fibroblasts (hGFs) exposed to interleukin (IL)-1\u03b2 to induce inflammation were treated with five different capsules of MIM-seq for 3 days or with MIM-seq for 24 days. Subsequently, MIM-seq was analyzed in a 3D model of human tissue equivalent of gingiva (GTE) under the same inflammatory stimulus. Simultaneously, a non-IL-1\u03b2-treated control and a vehicle were included. The effects of the treatments on cytotoxicity, collagen deposition, and the secreted levels of IL-1\u03b1, IL-6, prostaglandin E2 (PGE2), matrix metalloproteinase-1 (MMP-1), and tissue inhibitor of metalloproteinases-1 (TIMP-1) were evaluated. None of the tested items were cytotoxic. The complete sequence of MIM-seq decreased PGE2 release and restored collagen deposition levels induced by IL-1\u03b2 treatment in hGFs exposed to IL-1\u03b2. MIM-seq treatment restored collagen production levels in both models. These promising preclinical findings suggest that MIM-seq should be further investigated for periodontitis treatment.<\/p>\n<\/div><\/div><div class=\"w-vwrapper usg_vwrapper_2 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_1 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/06\/ijms-24-10484.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_2 icon_atleft\" href=\"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/10484\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><div class=\"w-hwrapper usg_hwrapper_3 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_3 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_2 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/06\/ijms-24-10484.pdf\" target=\"_blank\" rel=\"noopener nofollow\">A Sequential Micro-Immunotherapy Medicine Increases Collagen Deposition in Human Gingival Fibroblasts and in an Engineered 3D Gingival Model under Inflammatory Conditions<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_4 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_3 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">International Journal of Molecular Sciences<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_4 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Ferr\u00e0, M., Munar, M., Floris, I., Ramis, J.M., Monjo, M., Garc\u00eda, L.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_6 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2023<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_2 with_collapsible_content\" data-content-height=\"200px\"><div><p style=\"text-align: justify;\">Periodontal therapies use immune mediators, but their side effects can increase with dosage. Micro-immunotherapy (MI) is a promising alternative that employs immune regulators at low and ultralow doses to minimize adverse effects. In this study, the effects of 5 capsules and the entire 10-capsule sequence of the sequential MI medicine (MIM-seq) were tested in two in vitro models of periodontitis. Firstly, human gingival fibroblasts (hGFs) exposed to interleukin (IL)-1\u03b2 to induce inflammation were treated with five different capsules of MIM-seq for 3 days or with MIM-seq for 24 days. Subsequently, MIM-seq was analyzed in a 3D model of human tissue equivalent of gingiva (GTE) under the same inflammatory stimulus. Simultaneously, a non-IL-1\u03b2-treated control and a vehicle were included. The effects of the treatments on cytotoxicity, collagen deposition, and the secreted levels of IL-1\u03b1, IL-6, prostaglandin E2 (PGE2), matrix metalloproteinase-1 (MMP-1), and tissue inhibitor of metalloproteinases-1 (TIMP-1) were evaluated. None of the tested items were cytotoxic. The complete sequence of MIM-seq decreased PGE2 release and restored collagen deposition levels induced by IL-1\u03b2 treatment in hGFs exposed to IL-1\u03b2. MIM-seq treatment restored collagen production levels in both models. These promising preclinical findings suggest that MIM-seq should be further investigated for periodontitis treatment.<\/p>\n<\/div><div class=\"toggle-links align_none\"><button class=\"collapsible-content-more\">Read more<\/button><button class=\"collapsible-content-less\">Show less<\/button><\/div><\/div><div class=\"w-vwrapper usg_vwrapper_4 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_3 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/06\/ijms-24-10484.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_4 icon_atleft\" href=\"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/10484\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><\/div>\t\t<\/div>\n\t<\/article>\n\t<article class=\"w-grid-item size_1x1 post-3457 publicacion type-publicacion status-publish hentry category-publicaciones-cientificas-de\" data-id=\"3457\">\n\t\t<div class=\"w-grid-item-h\">\n\t\t\t\t\t\t<div class=\"w-hwrapper usg_hwrapper_2 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_1 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_1 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/How-an-Immune-Factor-Based-Formulation-of-Micro-Immunotherapy-Could-Interfere-with-the-Physiological-Processes-Involved-in-the-Atopic-March.pdf\" target=\"_blank\" rel=\"noopener nofollow\">How an Immune-Factor-Based Formulation of Micro-Immunotherapy Could Interfere with the Physiological Processes Involved in the Atopic March<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_1 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_1 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">International Journal of Molecular Sciences<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_2 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_5 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2023<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_1\"><p style=\"text-align: justify;\">Allergic diseases consist of improper inflammatory reactions to antigens and are currently an important healthcare concern, especially considering their increasing worldwide development in recent decades. The &#8220;atopic march&#8221; defines the paradigm of allergic diseases occurring in chronological order and displaying specific spatial manifestations, as they usually start as atopic dermatitis (AD) and food allergies during infancy and progressively evolve into allergic asthma (AA) and allergic rhinitis (AR) or rhino-conjunctivitis in childhood. Many immune cell subtypes and inflammatory factors are involved in these hypersensitivity reactions. In particular, the T helpers 2 (Th2) subset, through its cytokine signatures made of interleukins (ILs), such as IL-4, IL-5, IL-10, and IL-13, as well as mast cells and their related histamine pathways, contribute greatly to the perpetuation and evolution of the atopic march. By providing low doses (LD) and ultra-low doses (ULD) of ILs and immune factors to the body, micro-immunotherapy (MI) constitutes an interesting therapeutic strategy for the management of the atopic march and its symptoms. One of the aims of this review is to shed light on the current concept of the atopic march and the underlying immune reactions occurring during the IgE-mediated responses. Moreover, the different classes of traditional and innovative treatments employed in allergic diseases will also be discussed, with a special emphasis on the potential benefits of the MI medicine 2LALERG<sup>\u00ae<\/sup> formulation in this context.<\/p>\n<\/div><\/div><div class=\"w-vwrapper usg_vwrapper_2 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_1 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/How-an-Immune-Factor-Based-Formulation-of-Micro-Immunotherapy-Could-Interfere-with-the-Physiological-Processes-Involved-in-the-Atopic-March.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_2 icon_atleft\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36675006\/\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><div class=\"w-hwrapper usg_hwrapper_3 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_3 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_2 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/How-an-Immune-Factor-Based-Formulation-of-Micro-Immunotherapy-Could-Interfere-with-the-Physiological-Processes-Involved-in-the-Atopic-March.pdf\" target=\"_blank\" rel=\"noopener nofollow\">How an Immune-Factor-Based Formulation of Micro-Immunotherapy Could Interfere with the Physiological Processes Involved in the Atopic March<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_4 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_3 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">International Journal of Molecular Sciences<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_4 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_6 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2023<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_2 with_collapsible_content\" data-content-height=\"200px\"><div><p style=\"text-align: justify;\">Allergic diseases consist of improper inflammatory reactions to antigens and are currently an important healthcare concern, especially considering their increasing worldwide development in recent decades. The &#8220;atopic march&#8221; defines the paradigm of allergic diseases occurring in chronological order and displaying specific spatial manifestations, as they usually start as atopic dermatitis (AD) and food allergies during infancy and progressively evolve into allergic asthma (AA) and allergic rhinitis (AR) or rhino-conjunctivitis in childhood. Many immune cell subtypes and inflammatory factors are involved in these hypersensitivity reactions. In particular, the T helpers 2 (Th2) subset, through its cytokine signatures made of interleukins (ILs), such as IL-4, IL-5, IL-10, and IL-13, as well as mast cells and their related histamine pathways, contribute greatly to the perpetuation and evolution of the atopic march. By providing low doses (LD) and ultra-low doses (ULD) of ILs and immune factors to the body, micro-immunotherapy (MI) constitutes an interesting therapeutic strategy for the management of the atopic march and its symptoms. One of the aims of this review is to shed light on the current concept of the atopic march and the underlying immune reactions occurring during the IgE-mediated responses. Moreover, the different classes of traditional and innovative treatments employed in allergic diseases will also be discussed, with a special emphasis on the potential benefits of the MI medicine 2LALERG<sup>\u00ae<\/sup> formulation in this context.<\/p>\n<\/div><div class=\"toggle-links align_none\"><button class=\"collapsible-content-more\">Read more<\/button><button class=\"collapsible-content-less\">Show less<\/button><\/div><\/div><div class=\"w-vwrapper usg_vwrapper_4 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_3 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/How-an-Immune-Factor-Based-Formulation-of-Micro-Immunotherapy-Could-Interfere-with-the-Physiological-Processes-Involved-in-the-Atopic-March.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_4 icon_atleft\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36675006\/\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><\/div>\t\t<\/div>\n\t<\/article>\n\t<article class=\"w-grid-item size_1x1 post-3452 publicacion type-publicacion status-publish hentry category-publicaciones-cientificas-de\" data-id=\"3452\">\n\t\t<div class=\"w-grid-item-h\">\n\t\t\t\t\t\t<div class=\"w-hwrapper usg_hwrapper_2 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_1 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_1 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/Special-Focus-on-the-Cellular-Anti-Inflammatory-Effects-of-Several-Micro-Immunotherapy-Formulations.pdf\" target=\"_blank\" rel=\"noopener nofollow\">Special Focus on the Cellular Anti-Inflammatory Effects of Several Micro-Immunotherapy Formulations: Considerations Regarding Intestinal-, Immune-Axis-Related- and Neuronal-Inflammation Contexts<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_1 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_1 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">Journal of Inflammation Research<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_2 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_5 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2023<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_1\"><p id=\"sec-1title\" style=\"text-align: justify;\"><strong>Introduction<\/strong><\/p>\n<p style=\"text-align: justify;\">Chronic inflammation is a pernicious underlying status, well-known for its contribution to the progressive development of various diseases. In this regard, micro-immunotherapy (MI) might be a promising therapeutic strategy. MI employs low doses (LD) and ultra-low doses (ULD) of immune regulators in their formulations. In particular, as both IL-1\u03b2 and TNF-\u03b1 are often used at ULD in MI medicines (MIM), a special emphasis has been made on formulations that include these factors in their compositions.<\/p>\n<p style=\"text-align: justify;\"><strong>Methods<\/strong><\/p>\n<p style=\"text-align: justify;\">Several in vitro models have been employed in order to assess the effects of two unitary MIM consisting of ULD of IL-1\u03b2 and TNF-\u03b1 (u-MIM-1 and u-MIM-2, respectively), and four complex MIM (c-MIM-1, \u22122, \u22123 and \u22124) characterized by the presence of ULD of IL-1\u03b2 and TNF-\u03b1 amongst other factors. Thus, we first investigated the anti-inflammatory effects of u-MIM-1 and u-MIM-2 in a model of inflamed colon carcinoma cells. In addition, the anti-inflammatory potential of c-MIM-1, \u22122, \u22123 and \u22124, was assessed in in vitro models of intestinal and neuronal inflammation.<\/p>\n<p style=\"text-align: justify;\"><strong>Results<\/strong><\/p>\n<p class=\"p p-first-last\" style=\"text-align: justify;\">The results revealed that u-MIM-1 and u-MIM-2 both induced a slight decrease in the levels of IL-1\u03b2 and TNF-\u03b1 transcripts. Regarding the c-MIMs\u2019 effects, c-MIM-1 displayed the capability to restore the altered transepithelial electrical resistance in inflamed-HCoEpiC cells. Moreover, c-MIM-1 also slightly increased the expression of the junction-related protein claudin-1, both at the mRNA and protein levels. In addition, our in vitro investigations on c-MIM-2 and c-MIM-3 revealed their immune-modulatory effects in LPS-inflamed human monocytes, macrophages, and granulocytes, on the secretion of cytokines such as TNF-\u03b1, PGE2, and IL-6. Finally, c-MIM-4 restored the cell viability of LPS\/IFN-\u03b3-inflamed rat cortical neurons, while reducing the secretion of TNF-\u03b1 in rat glial cells.<\/p>\n<p class=\"p p-first-last\" style=\"text-align: justify;\"><strong>Discussion<\/strong><\/p>\n<div id=\"sec-4\" class=\"sec sec-last\">\n<p class=\"p p-first-last\" style=\"text-align: justify;\">Our results shed the light on the potential role of these MIM formulations in managing several chronic inflammation-related conditions.<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-vwrapper usg_vwrapper_2 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_1 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/Special-Focus-on-the-Cellular-Anti-Inflammatory-Effects-of-Several-Micro-Immunotherapy-Formulations.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_2 icon_atleft\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36536643\/\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><div class=\"w-hwrapper usg_hwrapper_3 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_3 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_2 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/Special-Focus-on-the-Cellular-Anti-Inflammatory-Effects-of-Several-Micro-Immunotherapy-Formulations.pdf\" target=\"_blank\" rel=\"noopener nofollow\">Special Focus on the Cellular Anti-Inflammatory Effects of Several Micro-Immunotherapy Formulations: Considerations Regarding Intestinal-, Immune-Axis-Related- and Neuronal-Inflammation Contexts<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_4 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_3 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">Journal of Inflammation Research<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_4 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_6 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2023<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_2 with_collapsible_content\" data-content-height=\"200px\"><div><p id=\"sec-1title\" style=\"text-align: justify;\"><strong>Introduction<\/strong><\/p>\n<p style=\"text-align: justify;\">Chronic inflammation is a pernicious underlying status, well-known for its contribution to the progressive development of various diseases. In this regard, micro-immunotherapy (MI) might be a promising therapeutic strategy. MI employs low doses (LD) and ultra-low doses (ULD) of immune regulators in their formulations. In particular, as both IL-1\u03b2 and TNF-\u03b1 are often used at ULD in MI medicines (MIM), a special emphasis has been made on formulations that include these factors in their compositions.<\/p>\n<p style=\"text-align: justify;\"><strong>Methods<\/strong><\/p>\n<p style=\"text-align: justify;\">Several in vitro models have been employed in order to assess the effects of two unitary MIM consisting of ULD of IL-1\u03b2 and TNF-\u03b1 (u-MIM-1 and u-MIM-2, respectively), and four complex MIM (c-MIM-1, \u22122, \u22123 and \u22124) characterized by the presence of ULD of IL-1\u03b2 and TNF-\u03b1 amongst other factors. Thus, we first investigated the anti-inflammatory effects of u-MIM-1 and u-MIM-2 in a model of inflamed colon carcinoma cells. In addition, the anti-inflammatory potential of c-MIM-1, \u22122, \u22123 and \u22124, was assessed in in vitro models of intestinal and neuronal inflammation.<\/p>\n<p style=\"text-align: justify;\"><strong>Results<\/strong><\/p>\n<p class=\"p p-first-last\" style=\"text-align: justify;\">The results revealed that u-MIM-1 and u-MIM-2 both induced a slight decrease in the levels of IL-1\u03b2 and TNF-\u03b1 transcripts. Regarding the c-MIMs\u2019 effects, c-MIM-1 displayed the capability to restore the altered transepithelial electrical resistance in inflamed-HCoEpiC cells. Moreover, c-MIM-1 also slightly increased the expression of the junction-related protein claudin-1, both at the mRNA and protein levels. In addition, our in vitro investigations on c-MIM-2 and c-MIM-3 revealed their immune-modulatory effects in LPS-inflamed human monocytes, macrophages, and granulocytes, on the secretion of cytokines such as TNF-\u03b1, PGE2, and IL-6. Finally, c-MIM-4 restored the cell viability of LPS\/IFN-\u03b3-inflamed rat cortical neurons, while reducing the secretion of TNF-\u03b1 in rat glial cells.<\/p>\n<p class=\"p p-first-last\" style=\"text-align: justify;\"><strong>Discussion<\/strong><\/p>\n<div id=\"sec-4\" class=\"sec sec-last\">\n<p class=\"p p-first-last\" style=\"text-align: justify;\">Our results shed the light on the potential role of these MIM formulations in managing several chronic inflammation-related conditions.<\/p>\n<\/div>\n<\/div><div class=\"toggle-links align_none\"><button class=\"collapsible-content-more\">Read more<\/button><button class=\"collapsible-content-less\">Show less<\/button><\/div><\/div><div class=\"w-vwrapper usg_vwrapper_4 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_3 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/Special-Focus-on-the-Cellular-Anti-Inflammatory-Effects-of-Several-Micro-Immunotherapy-Formulations.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_4 icon_atleft\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36536643\/\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><\/div>\t\t<\/div>\n\t<\/article>\n\t<article class=\"w-grid-item size_1x1 post-3443 publicacion type-publicacion status-publish hentry category-publicaciones-cientificas-de\" data-id=\"3443\">\n\t\t<div class=\"w-grid-item-h\">\n\t\t\t\t\t\t<div class=\"w-hwrapper usg_hwrapper_2 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_1 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_1 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/The-Unitary-Micro-Immunotherapy-Medicine-Interferon-y-4-CH-Displays-Similar-Immunostimulatory.pdf\" target=\"_blank\" rel=\"noopener nofollow\">The Unitary Micro-Immunotherapy Medicine Interferon-y (4 CH) Displays Similar Immunostimulatory and Immunomodulatory Effects than Those of Biologically Active Human Interferon-\u03b3 on Various Cell Types<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_1 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_1 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">International Journal of Molecular Sciences<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_2 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Chatelais, M., Fekir, K., Brulefert, A., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_5 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2022<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_1\"><p style=\"text-align: justify;\">As a cytokine, gamma-interferon (IFN-\u03b3) is considered a key player in the fine-tuned orchestration of immune responses. The extreme cellular sensitivity to cytokines is attested by the fact that very few of these bioactive molecules per cell are enough to trigger cellular functions. These findings can, at least partially, explain how\/why homeopathically-prepared cytokines, and especially micro-immunotherapy (MI) medicines, are able to drive cellular responses. We focused our fundamental research on a unitary MI preparation of IFN-\u03b3, specifically employed at 4 CH, manufactured and impregnated onto sucrose-lactose pillules as all other MI medicines. We assessed the IFN-\u03b3 concentration in the medium after dilution of the IFN-\u03b3 (4 CH)-bearing pillules and we evaluated in vitro drug responses in a wide range of immune cells, and in endothelial cells. Our results showed that IFN-\u03b3 (4 CH) stimulated the proliferation, the activation and the phagocytic capabilities of primary immune cells, as well as modulated their cytokine-secretion and immunity-related markers&#8217; expression in a trend that is quite comparable with the well-recognized biological effects induced by IFN-\u03b3. Altogether, these data provide novel and additional evidences on MI medicines, and specifically when active substances are prepared at 4 CH, thus suggesting the need for more investigations.<\/p>\n<\/div><\/div><div class=\"w-vwrapper usg_vwrapper_2 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_1 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/The-Unitary-Micro-Immunotherapy-Medicine-Interferon-y-4-CH-Displays-Similar-Immunostimulatory.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_2 icon_atleft\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35216428\/\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><div class=\"w-hwrapper usg_hwrapper_3 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_3 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_2 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/The-Unitary-Micro-Immunotherapy-Medicine-Interferon-y-4-CH-Displays-Similar-Immunostimulatory.pdf\" target=\"_blank\" rel=\"noopener nofollow\">The Unitary Micro-Immunotherapy Medicine Interferon-y (4 CH) Displays Similar Immunostimulatory and Immunomodulatory Effects than Those of Biologically Active Human Interferon-\u03b3 on Various Cell Types<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_4 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_3 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">International Journal of Molecular Sciences<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_4 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Chatelais, M., Fekir, K., Brulefert, A., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_6 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2022<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_2 with_collapsible_content\" data-content-height=\"200px\"><div><p style=\"text-align: justify;\">As a cytokine, gamma-interferon (IFN-\u03b3) is considered a key player in the fine-tuned orchestration of immune responses. The extreme cellular sensitivity to cytokines is attested by the fact that very few of these bioactive molecules per cell are enough to trigger cellular functions. These findings can, at least partially, explain how\/why homeopathically-prepared cytokines, and especially micro-immunotherapy (MI) medicines, are able to drive cellular responses. We focused our fundamental research on a unitary MI preparation of IFN-\u03b3, specifically employed at 4 CH, manufactured and impregnated onto sucrose-lactose pillules as all other MI medicines. We assessed the IFN-\u03b3 concentration in the medium after dilution of the IFN-\u03b3 (4 CH)-bearing pillules and we evaluated in vitro drug responses in a wide range of immune cells, and in endothelial cells. Our results showed that IFN-\u03b3 (4 CH) stimulated the proliferation, the activation and the phagocytic capabilities of primary immune cells, as well as modulated their cytokine-secretion and immunity-related markers&#8217; expression in a trend that is quite comparable with the well-recognized biological effects induced by IFN-\u03b3. Altogether, these data provide novel and additional evidences on MI medicines, and specifically when active substances are prepared at 4 CH, thus suggesting the need for more investigations.<\/p>\n<\/div><div class=\"toggle-links align_none\"><button class=\"collapsible-content-more\">Read more<\/button><button class=\"collapsible-content-less\">Show less<\/button><\/div><\/div><div class=\"w-vwrapper usg_vwrapper_4 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_3 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/The-Unitary-Micro-Immunotherapy-Medicine-Interferon-y-4-CH-Displays-Similar-Immunostimulatory.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_4 icon_atleft\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35216428\/\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><\/div>\t\t<\/div>\n\t<\/article>\n\t<article class=\"w-grid-item size_1x1 post-1907 publicacion type-publicacion status-publish hentry category-publicaciones-cientificas-de\" data-id=\"1907\">\n\t\t<div class=\"w-grid-item-h\">\n\t\t\t\t\t\t<div class=\"w-hwrapper usg_hwrapper_2 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_1 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_1 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2022\/09\/fr_ijms-23-06059-v2.pdf\" target=\"_blank\" rel=\"noopener nofollow\">A Micro-Immunotherapy Sequential Medicine MIM-seq Displays Immunomodulatory Effects on Human Macrophages and Anti-Tumor Properties towards In Vitro 2D and 3D Models of Colon Carcinoma and in an In Vivo Subcutaneous Xenograft Colon Carcinoma Model<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_1 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_1 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">International Journal of Molecular Sciences <\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_2 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Marchesi, I., Fiorentino, F. P., Chatelais, M., Libera, N., Appel, K., Lejeune, B., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_5 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2022<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_1\"><p style=\"text-align: justify;\">In this study, the immunomodulatory effects of a sequential micro-immunotherapy medicine, referred as MIM-seq, were appraised in human primary M1 and M2 macrophages, in which the secretion of pro-inflammatory cytokines, such as interleukin (IL)-1\u03b2, IL-6, IL-12, IL-23, and tumor necrosis factor (TNF)-alpha, was inhibited. In addition, the potential anti-proliferative effects of MIM-seq on tumor cells was assessed in three models of colorectal cancer (CRC): an in vitro two-dimensions (2D) model of HCT-116 cells, an in vitro tri-dimensional (3D) model of spheroids, and an in vivo model of subcutaneous xenografted mice. In these models, MIM-seq displayed anti-proliferative effects when compared with the vehicle. In vivo, the tumor growth was slightly reduced in MIM-seq-treated animals. Moreover, MIM-seq could slightly reduce the growth of our spheroid models, especially under serum-deprivation. When MIM-seq was combined with two well-known anti-cancerogenic agents, either resveratrol or etoposide, MIM-seq could even further reduce the spheroid\u2019s volume, pointing up the need to further assess whether MIM-seq could be beneficial for CRC patients as an adjuvant therapy. Altogether, these data suggest that MIM-seq could have anti-tumor properties against CRC and an immunomodulatory effect towards the mediators of inflammation, whose systemic dysregulation is considered to be a poor prognosis for patients.<\/p>\n<\/div><\/div><div class=\"w-vwrapper usg_vwrapper_2 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_1 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2022\/09\/fr_ijms-23-06059-v2.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_2 icon_atleft\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35682738\/\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><div class=\"w-hwrapper usg_hwrapper_3 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_3 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_2 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2022\/09\/fr_ijms-23-06059-v2.pdf\" target=\"_blank\" rel=\"noopener nofollow\">A Micro-Immunotherapy Sequential Medicine MIM-seq Displays Immunomodulatory Effects on Human Macrophages and Anti-Tumor Properties towards In Vitro 2D and 3D Models of Colon Carcinoma and in an In Vivo Subcutaneous Xenograft Colon Carcinoma Model<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_4 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_3 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">International Journal of Molecular Sciences <\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_4 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Marchesi, I., Fiorentino, F. P., Chatelais, M., Libera, N., Appel, K., Lejeune, B., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_6 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2022<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_2 with_collapsible_content\" data-content-height=\"200px\"><div><p style=\"text-align: justify;\">In this study, the immunomodulatory effects of a sequential micro-immunotherapy medicine, referred as MIM-seq, were appraised in human primary M1 and M2 macrophages, in which the secretion of pro-inflammatory cytokines, such as interleukin (IL)-1\u03b2, IL-6, IL-12, IL-23, and tumor necrosis factor (TNF)-alpha, was inhibited. In addition, the potential anti-proliferative effects of MIM-seq on tumor cells was assessed in three models of colorectal cancer (CRC): an in vitro two-dimensions (2D) model of HCT-116 cells, an in vitro tri-dimensional (3D) model of spheroids, and an in vivo model of subcutaneous xenografted mice. In these models, MIM-seq displayed anti-proliferative effects when compared with the vehicle. In vivo, the tumor growth was slightly reduced in MIM-seq-treated animals. Moreover, MIM-seq could slightly reduce the growth of our spheroid models, especially under serum-deprivation. When MIM-seq was combined with two well-known anti-cancerogenic agents, either resveratrol or etoposide, MIM-seq could even further reduce the spheroid\u2019s volume, pointing up the need to further assess whether MIM-seq could be beneficial for CRC patients as an adjuvant therapy. Altogether, these data suggest that MIM-seq could have anti-tumor properties against CRC and an immunomodulatory effect towards the mediators of inflammation, whose systemic dysregulation is considered to be a poor prognosis for patients.<\/p>\n<\/div><div class=\"toggle-links align_none\"><button class=\"collapsible-content-more\">Read more<\/button><button class=\"collapsible-content-less\">Show less<\/button><\/div><\/div><div class=\"w-vwrapper usg_vwrapper_4 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_3 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2022\/09\/fr_ijms-23-06059-v2.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_4 icon_atleft\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35682738\/\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><\/div>\t\t<\/div>\n\t<\/article>\n\t<article class=\"w-grid-item size_1x1 post-1914 publicacion type-publicacion status-publish hentry category-publicaciones-cientificas-de\" data-id=\"1914\">\n\t\t<div class=\"w-grid-item-h\">\n\t\t\t\t\t\t<div class=\"w-hwrapper usg_hwrapper_2 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_1 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_1 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2022\/09\/fr_ijms-23-00110-v2.pdf\" target=\"_blank\" rel=\"noopener nofollow\">The Micro-Immunotherapy Medicine 2LEID\u00ae Exhibits an Immunostimulant Effect by Boosting Both Innate and Adaptive Immune Responses<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_1 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_1 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">International Journal of Molecular Sciences <\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_2 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Chatelais, M., Fekir, K., Fauconnier, L., Mellier, M., Togbe, D., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_5 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2021<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_1\"><p style=\"text-align: justify;\">This study aimed at evaluating the effects of the micro-immunotherapy medicine (MIM) 2LEID\u00ae, both in vitro and in vivo, on several components of the innate and adaptive immune system. MIM increased the phagocytic activity of macrophages, and it augmented the expression of the activation markers CD69 and HLA-DR in NK cells and monocytes\/macrophages, respectively. The effect of MIM was evaluated in a model of respiratory infection induced by\u00a0<i>influenza A<\/i>\u00a0virus administration to immunocompetent mice in which it was able to improve neutrophil recruitment within the lungs (<i>p<\/i>\u00a0= 0.1051) and slightly increased the circulating levels of IgM (<i>p<\/i>\u00a0= 0.1655). Furthermore, MIM stimulated the proliferation of CD3-primed T lymphocytes and decreased the secretion of the immunosuppressive cytokine IL-10 in CD14+-derived macrophages. Human umbilical vein endothelial cells were finally used to explore the effect of MIM on endothelial cells, in which it slightly increased the expression of immune-related markers such as HLA-I, CD137L, GITRL, PD-L1 and ICAM-1. In conclusion, the present study suggests that MIM might be a promising nonspecific (without antigen specificity) immunostimulant drug in preventing and early treating respiratory infections, but not only exclusively, as it would gently support several facets of the immune system and host defenses.<\/p>\n<\/div><\/div><div class=\"w-vwrapper usg_vwrapper_2 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_1 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2022\/09\/fr_ijms-23-00110-v2.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_2 icon_atleft\" href=\"https:\/\/www.mdpi.com\/1422-0067\/23\/1\/110\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><div class=\"w-hwrapper usg_hwrapper_3 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_3 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_2 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2022\/09\/fr_ijms-23-00110-v2.pdf\" target=\"_blank\" rel=\"noopener nofollow\">The Micro-Immunotherapy Medicine 2LEID\u00ae Exhibits an Immunostimulant Effect by Boosting Both Innate and Adaptive Immune Responses<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_4 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_3 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">International Journal of Molecular Sciences <\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_4 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Chatelais, M., Fekir, K., Fauconnier, L., Mellier, M., Togbe, D., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_6 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2021<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_2 with_collapsible_content\" data-content-height=\"200px\"><div><p style=\"text-align: justify;\">This study aimed at evaluating the effects of the micro-immunotherapy medicine (MIM) 2LEID\u00ae, both in vitro and in vivo, on several components of the innate and adaptive immune system. MIM increased the phagocytic activity of macrophages, and it augmented the expression of the activation markers CD69 and HLA-DR in NK cells and monocytes\/macrophages, respectively. The effect of MIM was evaluated in a model of respiratory infection induced by\u00a0<i>influenza A<\/i>\u00a0virus administration to immunocompetent mice in which it was able to improve neutrophil recruitment within the lungs (<i>p<\/i>\u00a0= 0.1051) and slightly increased the circulating levels of IgM (<i>p<\/i>\u00a0= 0.1655). Furthermore, MIM stimulated the proliferation of CD3-primed T lymphocytes and decreased the secretion of the immunosuppressive cytokine IL-10 in CD14+-derived macrophages. Human umbilical vein endothelial cells were finally used to explore the effect of MIM on endothelial cells, in which it slightly increased the expression of immune-related markers such as HLA-I, CD137L, GITRL, PD-L1 and ICAM-1. In conclusion, the present study suggests that MIM might be a promising nonspecific (without antigen specificity) immunostimulant drug in preventing and early treating respiratory infections, but not only exclusively, as it would gently support several facets of the immune system and host defenses.<\/p>\n<\/div><div class=\"toggle-links align_none\"><button class=\"collapsible-content-more\">Read more<\/button><button class=\"collapsible-content-less\">Show less<\/button><\/div><\/div><div class=\"w-vwrapper usg_vwrapper_4 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_3 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2022\/09\/fr_ijms-23-00110-v2.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_4 icon_atleft\" href=\"https:\/\/www.mdpi.com\/1422-0067\/23\/1\/110\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><\/div>\t\t<\/div>\n\t<\/article>\n\t<article class=\"w-grid-item size_1x1 post-3489 publicacion type-publicacion status-publish hentry category-publicaciones-cientificas-de\" data-id=\"3489\">\n\t\t<div class=\"w-grid-item-h\">\n\t\t\t\t\t\t<div class=\"w-hwrapper usg_hwrapper_2 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_1 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_1 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/566-Article-Text-2415-3-10-20211207.pdf\" target=\"_blank\" rel=\"noopener nofollow\">High Risk Human Papillomavirus genital infections in asymptomatic population: effectiveness of Micro-Immunotherapy<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_1 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_1 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">International Journal of High Dilution Research<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_2 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Mazzoli, S., Cai, T., Meacci, F., Addonisio, P., Dorfman, P.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_5 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2021<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_1\"><p><strong>Background<\/strong><\/p>\n<p>Persistent infection with high-risk human papillomavirus (HR-HPV) is the primary cause for the development of various anogenital cancers in females and males. Most infections are either latent or subclinical and the majority occur as asymptomatic. HPV infections are not currently treatable by antiviral compounds. Micro-immunotherapy (MI) medications using high dilutions of cytokines and specific nucleotide sequences have been developed to treat targeted viral infections and are currently prescribed in medical practice as immune regulators: 2L\u00aePAPI (Labo&#8217;life) is indicated for HPV infection and may represent a new therapeutic approach.<\/p>\n<p><strong>Aims<\/strong><\/p>\n<p>This exploratory study was to assess the effectiveness of 2L\u00aePAPI on HPV infection eradication in HR-HPV infected asymptomatic patients attending an STD Centre in a long-term microbiological follow-up population survey.<\/p>\n<p><strong>Methodology<\/strong><\/p>\n<p>Adult patients of both genders, diagnosed with HR-HPV infection, with no evidence of symptomatic HPV or anogenital cancer, were followed during a 2 year-period (2009-2010). Selected patients had not previously been vaccinated for HPV or treated with medications having an impact on the immune system. HPV testing was performed on biological samples using PCR detection (Innogenetics, Italy). In addition, detection of E6\/E7 mRNA of five carcinogenic HPV types was performed by EasyQ HPV (BioMerieux, Italy). HPV-positives were requested by their urology specialist to take 2L\u00aePAPI (composition in table 1) during 4 months (1 caps\/day by sublingual route). Globally 46 patients were followed: 23 treated with MI medication, and 23 not treated.<\/p>\n<p><strong>Results<\/strong><\/p>\n<p>One third of selected patients were lost at the control visit (15\/46). At the end of the study period, HR-HPV negativity was observed in 50% (8\/16) of patients under MI medication in comparison with only 7% (1\/15) of the non treated patients who were HPV-DNA negative at the follow-up visit (p=0.01071, Mid-P exact test). This result is in accordance with our previous results which showed long lasting persistence of HR-HPV infection in a male cohort.<\/p>\n<p><strong>Conclusions<\/strong><\/p>\n<p>The relevant percentage of lost patients at follow-up reflects the scarce information and awareness of this infection within asymptomatic people in Italy. 2L\u00aePAPI was efficient in eradicating 50% of HR-HPV infections in treated patients, including 60% of HPV-16. These promising data emphasize the importance of redirecting immune responses in viral infections.<\/p>\n<\/div><\/div><div class=\"w-vwrapper usg_vwrapper_2 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_1 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/566-Article-Text-2415-3-10-20211207.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_2 icon_atleft\" href=\"https:\/\/www.highdilution.org\/index.php\/ijhdr\/article\/view\/566\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><div class=\"w-hwrapper usg_hwrapper_3 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_3 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_2 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/566-Article-Text-2415-3-10-20211207.pdf\" target=\"_blank\" rel=\"noopener nofollow\">High Risk Human Papillomavirus genital infections in asymptomatic population: effectiveness of Micro-Immunotherapy<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_4 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_3 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">International Journal of High Dilution Research<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_4 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Mazzoli, S., Cai, T., Meacci, F., Addonisio, P., Dorfman, P.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_6 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2021<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_2 with_collapsible_content\" data-content-height=\"200px\"><div><p><strong>Background<\/strong><\/p>\n<p>Persistent infection with high-risk human papillomavirus (HR-HPV) is the primary cause for the development of various anogenital cancers in females and males. Most infections are either latent or subclinical and the majority occur as asymptomatic. HPV infections are not currently treatable by antiviral compounds. Micro-immunotherapy (MI) medications using high dilutions of cytokines and specific nucleotide sequences have been developed to treat targeted viral infections and are currently prescribed in medical practice as immune regulators: 2L\u00aePAPI (Labo&#8217;life) is indicated for HPV infection and may represent a new therapeutic approach.<\/p>\n<p><strong>Aims<\/strong><\/p>\n<p>This exploratory study was to assess the effectiveness of 2L\u00aePAPI on HPV infection eradication in HR-HPV infected asymptomatic patients attending an STD Centre in a long-term microbiological follow-up population survey.<\/p>\n<p><strong>Methodology<\/strong><\/p>\n<p>Adult patients of both genders, diagnosed with HR-HPV infection, with no evidence of symptomatic HPV or anogenital cancer, were followed during a 2 year-period (2009-2010). Selected patients had not previously been vaccinated for HPV or treated with medications having an impact on the immune system. HPV testing was performed on biological samples using PCR detection (Innogenetics, Italy). In addition, detection of E6\/E7 mRNA of five carcinogenic HPV types was performed by EasyQ HPV (BioMerieux, Italy). HPV-positives were requested by their urology specialist to take 2L\u00aePAPI (composition in table 1) during 4 months (1 caps\/day by sublingual route). Globally 46 patients were followed: 23 treated with MI medication, and 23 not treated.<\/p>\n<p><strong>Results<\/strong><\/p>\n<p>One third of selected patients were lost at the control visit (15\/46). At the end of the study period, HR-HPV negativity was observed in 50% (8\/16) of patients under MI medication in comparison with only 7% (1\/15) of the non treated patients who were HPV-DNA negative at the follow-up visit (p=0.01071, Mid-P exact test). This result is in accordance with our previous results which showed long lasting persistence of HR-HPV infection in a male cohort.<\/p>\n<p><strong>Conclusions<\/strong><\/p>\n<p>The relevant percentage of lost patients at follow-up reflects the scarce information and awareness of this infection within asymptomatic people in Italy. 2L\u00aePAPI was efficient in eradicating 50% of HR-HPV infections in treated patients, including 60% of HPV-16. These promising data emphasize the importance of redirecting immune responses in viral infections.<\/p>\n<\/div><div class=\"toggle-links align_none\"><button class=\"collapsible-content-more\">Read more<\/button><button class=\"collapsible-content-less\">Show less<\/button><\/div><\/div><div class=\"w-vwrapper usg_vwrapper_4 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_3 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/566-Article-Text-2415-3-10-20211207.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_4 icon_atleft\" href=\"https:\/\/www.highdilution.org\/index.php\/ijhdr\/article\/view\/566\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><\/div>\t\t<\/div>\n\t<\/article>\n\t<article class=\"w-grid-item size_1x1 post-3438 publicacion type-publicacion status-publish hentry category-publicaciones-cientificas-de\" data-id=\"3438\">\n\t\t<div class=\"w-grid-item-h\">\n\t\t\t\t\t\t<div class=\"w-hwrapper usg_hwrapper_2 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_1 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_1 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/Ultra-Low-Dose-Cytokines-in-Rheumatoid-Arthritis-Three-Birds-with-One-Stone-as-the-Rationale-of-the-2LARTH\u00ae-Micro-Immunotherapy-Treatment.pdf\" target=\"_blank\" rel=\"noopener nofollow\">Ultra-Low Dose Cytokines in Rheumatoid Arthritis, Three Birds with One Stone as the Rationale of the 2LARTH\u00ae Micro-Immunotherapy Treatment<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_1 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_1 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">International Journal of Molecular Sciences<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_2 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Lejeune, B., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_5 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2021<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_1\"><p style=\"text-align: justify;\">Tumor necrosis factor-\u03b1 (TNF-\u03b1) and interleukin-1\u03b2 (IL-1\u03b2) are two cytokines involved in the perpetuation of the chronic inflammation state characterizing rheumatoid arthritis (RA). Significant advances in the treatment of this pathology have been made over the past ten years, partially through the development of anti-TNF and anti-IL-1 therapies. However, major side effects still persist and new alternative therapies should be considered. The formulation of the micro-immunotherapy medicine (MIM) 2LARTH<sup>\u00ae<\/sup> uses ultra-low doses (ULD) of TNF-\u03b1, IL-1\u03b2, and IL-2, in association with other immune factors, to gently restore the body\u2019s homeostasis. The first part of this review aims at delineating the pivotal roles played by IL-1\u03b2 and TNF-\u03b1 in RA physiopathology, leading to the development of anti-TNF and anti-IL-1 therapeutic agents. In a second part, an emphasis will be made on explaining the rationale of using multiple therapeutic targets, including both IL-1\u03b2 and TNF-\u03b1 in 2LARTH<sup>\u00ae<\/sup> medicine. Particular attention will be paid to the ULD of those two main pro-inflammatory factors in order to counteract their overexpression through the lens of their molecular implication in RA pathogenesis.<\/p>\n<\/div><\/div><div class=\"w-vwrapper usg_vwrapper_2 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_1 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/Ultra-Low-Dose-Cytokines-in-Rheumatoid-Arthritis-Three-Birds-with-One-Stone-as-the-Rationale-of-the-2LARTH\u00ae-Micro-Immunotherapy-Treatment.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_2 icon_atleft\" href=\"https:\/\/www.mdpi.com\/1422-0067\/22\/13\/6717\/htm\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><div class=\"w-hwrapper usg_hwrapper_3 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_3 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_2 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/Ultra-Low-Dose-Cytokines-in-Rheumatoid-Arthritis-Three-Birds-with-One-Stone-as-the-Rationale-of-the-2LARTH\u00ae-Micro-Immunotherapy-Treatment.pdf\" target=\"_blank\" rel=\"noopener nofollow\">Ultra-Low Dose Cytokines in Rheumatoid Arthritis, Three Birds with One Stone as the Rationale of the 2LARTH\u00ae Micro-Immunotherapy Treatment<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_4 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_3 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">International Journal of Molecular Sciences<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_4 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Jacques, C., Lejeune, B., Floris, I.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_6 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2021<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_2 with_collapsible_content\" data-content-height=\"200px\"><div><p style=\"text-align: justify;\">Tumor necrosis factor-\u03b1 (TNF-\u03b1) and interleukin-1\u03b2 (IL-1\u03b2) are two cytokines involved in the perpetuation of the chronic inflammation state characterizing rheumatoid arthritis (RA). Significant advances in the treatment of this pathology have been made over the past ten years, partially through the development of anti-TNF and anti-IL-1 therapies. However, major side effects still persist and new alternative therapies should be considered. The formulation of the micro-immunotherapy medicine (MIM) 2LARTH<sup>\u00ae<\/sup> uses ultra-low doses (ULD) of TNF-\u03b1, IL-1\u03b2, and IL-2, in association with other immune factors, to gently restore the body\u2019s homeostasis. The first part of this review aims at delineating the pivotal roles played by IL-1\u03b2 and TNF-\u03b1 in RA physiopathology, leading to the development of anti-TNF and anti-IL-1 therapeutic agents. In a second part, an emphasis will be made on explaining the rationale of using multiple therapeutic targets, including both IL-1\u03b2 and TNF-\u03b1 in 2LARTH<sup>\u00ae<\/sup> medicine. Particular attention will be paid to the ULD of those two main pro-inflammatory factors in order to counteract their overexpression through the lens of their molecular implication in RA pathogenesis.<\/p>\n<\/div><div class=\"toggle-links align_none\"><button class=\"collapsible-content-more\">Read more<\/button><button class=\"collapsible-content-less\">Show less<\/button><\/div><\/div><div class=\"w-vwrapper usg_vwrapper_4 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_3 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/Ultra-Low-Dose-Cytokines-in-Rheumatoid-Arthritis-Three-Birds-with-One-Stone-as-the-Rationale-of-the-2LARTH\u00ae-Micro-Immunotherapy-Treatment.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_4 icon_atleft\" href=\"https:\/\/www.mdpi.com\/1422-0067\/22\/13\/6717\/htm\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><\/div>\t\t<\/div>\n\t<\/article>\n\t<article class=\"w-grid-item size_1x1 post-3433 publicacion type-publicacion status-publish hentry category-publicaciones-cientificas-de\" data-id=\"3433\">\n\t\t<div class=\"w-grid-item-h\">\n\t\t\t\t\t\t<div class=\"w-hwrapper usg_hwrapper_2 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_1 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_1 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/BMP4-micro-immunotherapy-increases-collagen-deposition-and-reduces-PGE2-release-in-human-gingival-fibroblasts.pdf\" target=\"_blank\" rel=\"noopener nofollow\">BMP4 micro-immunotherapy increases collagen deposition and reduces PGE2 release in human gingival fibroblasts and increases tissue viability of engineered 3D gingiva under inflammatory conditions<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_1 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_1 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">Journal of Periodontology<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_2 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Ferr\u00e0, M., Munar, M., Garc\u00eda, L., Lejeune, B., Ramis, J.M., Monjo, M.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_5 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2020<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_1\"><p style=\"text-align: justify;\"><strong class=\"sub-title\">Background<\/strong><\/p>\n<p style=\"text-align: justify;\">We aimed to evaluate the effect of low doses (LD) bone morphogenetic protein-2 (BMP2) and BMP4 micro-immunotherapy (MI) in two in vitro models of periodontal wound healing\/regeneration.<\/p>\n<p style=\"text-align: justify;\"><strong class=\"sub-title\">Methods<\/strong><\/p>\n<p style=\"text-align: justify;\">We first evaluated the effect of LD of BMP2 and BMP4 MI on a 2D cell culture using human gingival fibroblasts (hGF) under inflammatory conditions induced by IL1\u03b2. Biocompatibility, inflammatory response (Prostaglandin E2 (PGE2) release), collagen deposition and release of extracellular matrix (ECM) organization-related enzymes (matrix metalloproteinase-1 (MMP1) and metalloproteinase inhibitor 1 (TIMP1)) were evaluated after short (3 days) and long-term (24 days) treatment with BMP2 or BMP4 MI. Then, given the results obtained in the 2D cell culture, LD BMP4 MI treatment was evaluated in a 3D cell culture model of human tissue equivalent of gingiva (GTE) under the same inflammatory stimulus, evaluating the biocompatibility, inflammatory response and effect on MMP1 and TIMP1 release.<\/p>\n<p style=\"text-align: justify;\"><strong class=\"sub-title\">Results<\/strong><\/p>\n<p style=\"text-align: justify;\">LD BMP4 was able to decrease the release of the inflammatory mediator PGE2 and completely re-establish the impaired collagen metabolism induced by IL1\u03b2 treatment. In the 3D model, LD BMP4 treatment improved tissue viability compared with the vehicle, with similar levels to 3D tissues without inflammation. No significant effects were observed on PGE2 levels nor MMP1\/TIMP1 ratio after LD BMP4 treatment, although a tendency to decrease PGE2 levels was observed after 3 days.<\/p>\n<p style=\"text-align: justify;\"><strong class=\"sub-title\">Conclusions<\/strong><\/p>\n<p style=\"text-align: justify;\">LD BMP4 MI treatment shows anti-inflammatory and regenerative properties on hGF, and improved viability of 3D gingiva under inflammatory conditions. LD BMP4 MI treatment could be used on primary prevention or maintenance care of periodontitis.<\/p>\n<\/div><\/div><div class=\"w-vwrapper usg_vwrapper_2 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_1 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/BMP4-micro-immunotherapy-increases-collagen-deposition-and-reduces-PGE2-release-in-human-gingival-fibroblasts.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_2 icon_atleft\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33393105\/\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><div class=\"w-hwrapper usg_hwrapper_3 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_3 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_2 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/BMP4-micro-immunotherapy-increases-collagen-deposition-and-reduces-PGE2-release-in-human-gingival-fibroblasts.pdf\" target=\"_blank\" rel=\"noopener nofollow\">BMP4 micro-immunotherapy increases collagen deposition and reduces PGE2 release in human gingival fibroblasts and increases tissue viability of engineered 3D gingiva under inflammatory conditions<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_4 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_3 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">Journal of Periodontology<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_4 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Ferr\u00e0, M., Munar, M., Garc\u00eda, L., Lejeune, B., Ramis, J.M., Monjo, M.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_6 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2020<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_2 with_collapsible_content\" data-content-height=\"200px\"><div><p style=\"text-align: justify;\"><strong class=\"sub-title\">Background<\/strong><\/p>\n<p style=\"text-align: justify;\">We aimed to evaluate the effect of low doses (LD) bone morphogenetic protein-2 (BMP2) and BMP4 micro-immunotherapy (MI) in two in vitro models of periodontal wound healing\/regeneration.<\/p>\n<p style=\"text-align: justify;\"><strong class=\"sub-title\">Methods<\/strong><\/p>\n<p style=\"text-align: justify;\">We first evaluated the effect of LD of BMP2 and BMP4 MI on a 2D cell culture using human gingival fibroblasts (hGF) under inflammatory conditions induced by IL1\u03b2. Biocompatibility, inflammatory response (Prostaglandin E2 (PGE2) release), collagen deposition and release of extracellular matrix (ECM) organization-related enzymes (matrix metalloproteinase-1 (MMP1) and metalloproteinase inhibitor 1 (TIMP1)) were evaluated after short (3 days) and long-term (24 days) treatment with BMP2 or BMP4 MI. Then, given the results obtained in the 2D cell culture, LD BMP4 MI treatment was evaluated in a 3D cell culture model of human tissue equivalent of gingiva (GTE) under the same inflammatory stimulus, evaluating the biocompatibility, inflammatory response and effect on MMP1 and TIMP1 release.<\/p>\n<p style=\"text-align: justify;\"><strong class=\"sub-title\">Results<\/strong><\/p>\n<p style=\"text-align: justify;\">LD BMP4 was able to decrease the release of the inflammatory mediator PGE2 and completely re-establish the impaired collagen metabolism induced by IL1\u03b2 treatment. In the 3D model, LD BMP4 treatment improved tissue viability compared with the vehicle, with similar levels to 3D tissues without inflammation. No significant effects were observed on PGE2 levels nor MMP1\/TIMP1 ratio after LD BMP4 treatment, although a tendency to decrease PGE2 levels was observed after 3 days.<\/p>\n<p style=\"text-align: justify;\"><strong class=\"sub-title\">Conclusions<\/strong><\/p>\n<p style=\"text-align: justify;\">LD BMP4 MI treatment shows anti-inflammatory and regenerative properties on hGF, and improved viability of 3D gingiva under inflammatory conditions. LD BMP4 MI treatment could be used on primary prevention or maintenance care of periodontitis.<\/p>\n<\/div><div class=\"toggle-links align_none\"><button class=\"collapsible-content-more\">Read more<\/button><button class=\"collapsible-content-less\">Show less<\/button><\/div><\/div><div class=\"w-vwrapper usg_vwrapper_4 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_3 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/BMP4-micro-immunotherapy-increases-collagen-deposition-and-reduces-PGE2-release-in-human-gingival-fibroblasts.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_4 icon_atleft\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33393105\/\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><\/div>\t\t<\/div>\n\t<\/article>\n\t<article class=\"w-grid-item size_1x1 post-1924 publicacion type-publicacion status-publish hentry category-publicaciones-cientificas-de\" data-id=\"1924\">\n\t\t<div class=\"w-grid-item-h\">\n\t\t\t\t\t\t<div class=\"w-hwrapper usg_hwrapper_2 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_1 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_1 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2022\/09\/The-Micro-Immunotherapy-Medicine-2LARTH\u00ae-Reduces-Inflammation-and-Symptoms-of-Rheumatoid-Arthritis-In-Vivo.pdf\" target=\"_blank\" rel=\"noopener nofollow\">The Micro-Immunotherapy Medicine 2LARTH\u00ae Reduces Inflammation and Symptoms of Rheumatoid Arthritis In Vivo<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_1 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_1 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">International Journal of Rheumatology <\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_2 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Floris, I., Garc\u00eda-Gonz\u00e1lez, V., Palomares, B., Appel, K., Lejeune, B.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_5 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2020<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_1\"><p style=\"text-align: justify;\">Rheumatoid arthritis (RA) is a chronic inflammatory joint disease, which can cause cartilage and bone damages as well\u00a0as pain and disability. In order to prevent disease progression, reduce pain, and major symptoms of RA, one good strategy consists\u00a0in targeting proinflammatory cytokines that have the key role in the vicious circle of synovial inflammation and pain. The micro-immunotherapy\u00a0medicine (MIM) 2LARTH\u00ae\u00a0targets cytokines involved in inflammation. The\u00a0aim of the study is to evaluate the\u00a0effect of the MIM compared to vehicle in an in vivo model of RA, induced in mice aer immunization with articular bovine type II\u00a0collagen.<\/p>\n<p style=\"text-align: justify;\"><strong>Methods<\/strong><\/p>\n<p style=\"text-align: justify;\">Vehicle and MIM were dissolved in pure water (1 capsule in 100 ml) and 100 \u03bcl was given by gavage daily for 14\u00a0days. To evaluate the severity of arthritis, wrist and ankle thickness was determined, paw edema was measured, and a clinical score\u00a0from 0 to 4 was established. Furthermore, histological analysis was performed. To evaluate systemic inflammation, circulating levels\u00a0of IL-1\u03b2 and TNF-\u03b1 were measured by ELISA.<\/p>\n<p style=\"text-align: justify;\"><strong>Results<\/strong><\/p>\n<p style=\"text-align: justify;\">Ankle thickness was found to be significantly reduced in MIM-treated mice\u00a0compared to vehicle-treated mice (P&lt; 0.05) and compared to untreated me (P&lt; 0.01). Paw edema was reduced, as well as clinical\u00a0score attributed to MIM-treated mice in comparison with vehicle-treated mice and untreated CIA mice (P&lt; 0.01). In line with\u00a0these results, histological analysis confirmed that MIM reduced inflammation and joint destruction in comparison to controls. No\u00a0significant changes were found in plasmatic IL-1\u03b2 levels between CIA and controls, while the levels of TNF-\u03b1 significantly increased\u00a0in the CIA group, and were lowered in MIM-treated mice (P&lt; 0.05 vs. vehicle and vs. CIA).<\/p>\n<p style=\"text-align: justify;\"><strong>Conclusion<\/strong><\/p>\n<p style=\"text-align: justify;\">The results indicate that\u00a0the tested medicine reduces inflammation, histological, and clinical signs of RA in a CIA model.<\/p>\n<\/div><\/div><div class=\"w-vwrapper usg_vwrapper_2 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_1 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2022\/09\/The-Micro-Immunotherapy-Medicine-2LARTH\u00ae-Reduces-Inflammation-and-Symptoms-of-Rheumatoid-Arthritis-In-Vivo.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_2 icon_atleft\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32180808\/\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><div class=\"w-hwrapper usg_hwrapper_3 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_3 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_2 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2022\/09\/The-Micro-Immunotherapy-Medicine-2LARTH\u00ae-Reduces-Inflammation-and-Symptoms-of-Rheumatoid-Arthritis-In-Vivo.pdf\" target=\"_blank\" rel=\"noopener nofollow\">The Micro-Immunotherapy Medicine 2LARTH\u00ae Reduces Inflammation and Symptoms of Rheumatoid Arthritis In Vivo<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_4 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_3 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">International Journal of Rheumatology <\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_4 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Floris, I., Garc\u00eda-Gonz\u00e1lez, V., Palomares, B., Appel, K., Lejeune, B.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_6 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2020<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_2 with_collapsible_content\" data-content-height=\"200px\"><div><p style=\"text-align: justify;\">Rheumatoid arthritis (RA) is a chronic inflammatory joint disease, which can cause cartilage and bone damages as well\u00a0as pain and disability. In order to prevent disease progression, reduce pain, and major symptoms of RA, one good strategy consists\u00a0in targeting proinflammatory cytokines that have the key role in the vicious circle of synovial inflammation and pain. The micro-immunotherapy\u00a0medicine (MIM) 2LARTH\u00ae\u00a0targets cytokines involved in inflammation. The\u00a0aim of the study is to evaluate the\u00a0effect of the MIM compared to vehicle in an in vivo model of RA, induced in mice aer immunization with articular bovine type II\u00a0collagen.<\/p>\n<p style=\"text-align: justify;\"><strong>Methods<\/strong><\/p>\n<p style=\"text-align: justify;\">Vehicle and MIM were dissolved in pure water (1 capsule in 100 ml) and 100 \u03bcl was given by gavage daily for 14\u00a0days. To evaluate the severity of arthritis, wrist and ankle thickness was determined, paw edema was measured, and a clinical score\u00a0from 0 to 4 was established. Furthermore, histological analysis was performed. To evaluate systemic inflammation, circulating levels\u00a0of IL-1\u03b2 and TNF-\u03b1 were measured by ELISA.<\/p>\n<p style=\"text-align: justify;\"><strong>Results<\/strong><\/p>\n<p style=\"text-align: justify;\">Ankle thickness was found to be significantly reduced in MIM-treated mice\u00a0compared to vehicle-treated mice (P&lt; 0.05) and compared to untreated me (P&lt; 0.01). Paw edema was reduced, as well as clinical\u00a0score attributed to MIM-treated mice in comparison with vehicle-treated mice and untreated CIA mice (P&lt; 0.01). In line with\u00a0these results, histological analysis confirmed that MIM reduced inflammation and joint destruction in comparison to controls. No\u00a0significant changes were found in plasmatic IL-1\u03b2 levels between CIA and controls, while the levels of TNF-\u03b1 significantly increased\u00a0in the CIA group, and were lowered in MIM-treated mice (P&lt; 0.05 vs. vehicle and vs. CIA).<\/p>\n<p style=\"text-align: justify;\"><strong>Conclusion<\/strong><\/p>\n<p style=\"text-align: justify;\">The results indicate that\u00a0the tested medicine reduces inflammation, histological, and clinical signs of RA in a CIA model.<\/p>\n<\/div><div class=\"toggle-links align_none\"><button class=\"collapsible-content-more\">Read more<\/button><button class=\"collapsible-content-less\">Show less<\/button><\/div><\/div><div class=\"w-vwrapper usg_vwrapper_4 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_3 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2022\/09\/The-Micro-Immunotherapy-Medicine-2LARTH\u00ae-Reduces-Inflammation-and-Symptoms-of-Rheumatoid-Arthritis-In-Vivo.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_4 icon_atleft\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32180808\/\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><\/div>\t\t<\/div>\n\t<\/article>\n\t<article class=\"w-grid-item size_1x1 post-1921 publicacion type-publicacion status-publish hentry category-publicaciones-cientificas-de\" data-id=\"1921\">\n\t\t<div class=\"w-grid-item-h\">\n\t\t\t\t\t\t<div class=\"w-hwrapper usg_hwrapper_2 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_1 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_1 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2022\/12\/Potential-Role-of-the-Micro-Immunotherapy-Medicine-2LALERG-in-the-Treatment-of-Pollen-Induced-Allergic-Inflammation.pdf\" target=\"_blank\" rel=\"noopener nofollow\">Potential Role of the Micro-Immunotherapy Medicine 2LALERG in the Treatment of Pollen-Induced Allergic Inflammation<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_1 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_1 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">Dose-Response Journal <\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_2 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Floris, I., Chenuet P., Togbe D., Volteau C., Lejeune B.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_5 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2020<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_1\"><p style=\"text-align: justify;\">In this study, we evaluated the efficacy of a micro-immunotherapy medicine (MIM), 2LALERG, in a preclinical model of allergic respiratory disease sensitized with birch pollen extract (BPE). BALB\/c mice were immunized with BPE, or saline solution, and were then challenged. Micro-immunotherapy medicine pillules were diluted in water, and 3 doses (0.75; 1.5; 3 mg\/mouse) were tested and compared to vehicle control (3 mg\/mouse). Treatments and vehicle were orally administered by gavage for 10 days. Micro-immunotherapy medicine (0.75 mg\/mouse) reduced the number of total cells as well as the levels of interleukin (IL)-13 in bronchoalveolar lavage fluid (BALF) compared to vehicle control. Eosinophils in BALF tended to be lower compared to vehicle group, and the difference is close to significance. Histological analysis in the lungs confirms a moderate effect of MIM (0.75 mg\/mice) on inflammatory infiltration and mucus production. Serum levels of IL-5 in MIM (0.75 mg\/mouse)-treated mice were lower compared to vehicle; IL-4 levels tended to be lower too. Total immunoglobulin E (IgE) decreased in serum of MIM (1.5 and 0.75 mg\/mouse) groups compared to vehicle control. Micro-immunotherapy medicine exerted the highest effect at the lowest dose tested. Micro-immunotherapy medicine resolved the local and systemic inflammation, even if partially, in a model of pollen-induced, IgE-mediated inflammation.<\/p>\n<\/div><\/div><div class=\"w-vwrapper usg_vwrapper_2 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_1 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2022\/12\/Potential-Role-of-the-Micro-Immunotherapy-Medicine-2LALERG-in-the-Treatment-of-Pollen-Induced-Allergic-Inflammation.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_2 icon_atleft\" href=\"https:\/\/journals.sagepub.com\/doi\/full\/10.1177\/1559325820914092\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><div class=\"w-hwrapper usg_hwrapper_3 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_3 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_2 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2022\/12\/Potential-Role-of-the-Micro-Immunotherapy-Medicine-2LALERG-in-the-Treatment-of-Pollen-Induced-Allergic-Inflammation.pdf\" target=\"_blank\" rel=\"noopener nofollow\">Potential Role of the Micro-Immunotherapy Medicine 2LALERG in the Treatment of Pollen-Induced Allergic Inflammation<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_4 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_3 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">Dose-Response Journal <\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_4 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Floris, I., Chenuet P., Togbe D., Volteau C., Lejeune B.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_6 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2020<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_2 with_collapsible_content\" data-content-height=\"200px\"><div><p style=\"text-align: justify;\">In this study, we evaluated the efficacy of a micro-immunotherapy medicine (MIM), 2LALERG, in a preclinical model of allergic respiratory disease sensitized with birch pollen extract (BPE). BALB\/c mice were immunized with BPE, or saline solution, and were then challenged. Micro-immunotherapy medicine pillules were diluted in water, and 3 doses (0.75; 1.5; 3 mg\/mouse) were tested and compared to vehicle control (3 mg\/mouse). Treatments and vehicle were orally administered by gavage for 10 days. Micro-immunotherapy medicine (0.75 mg\/mouse) reduced the number of total cells as well as the levels of interleukin (IL)-13 in bronchoalveolar lavage fluid (BALF) compared to vehicle control. Eosinophils in BALF tended to be lower compared to vehicle group, and the difference is close to significance. Histological analysis in the lungs confirms a moderate effect of MIM (0.75 mg\/mice) on inflammatory infiltration and mucus production. Serum levels of IL-5 in MIM (0.75 mg\/mouse)-treated mice were lower compared to vehicle; IL-4 levels tended to be lower too. Total immunoglobulin E (IgE) decreased in serum of MIM (1.5 and 0.75 mg\/mouse) groups compared to vehicle control. Micro-immunotherapy medicine exerted the highest effect at the lowest dose tested. Micro-immunotherapy medicine resolved the local and systemic inflammation, even if partially, in a model of pollen-induced, IgE-mediated inflammation.<\/p>\n<\/div><div class=\"toggle-links align_none\"><button class=\"collapsible-content-more\">Read more<\/button><button class=\"collapsible-content-less\">Show less<\/button><\/div><\/div><div class=\"w-vwrapper usg_vwrapper_4 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_3 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2022\/12\/Potential-Role-of-the-Micro-Immunotherapy-Medicine-2LALERG-in-the-Treatment-of-Pollen-Induced-Allergic-Inflammation.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_4 icon_atleft\" href=\"https:\/\/journals.sagepub.com\/doi\/full\/10.1177\/1559325820914092\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><\/div>\t\t<\/div>\n\t<\/article>\n\t<article class=\"w-grid-item size_1x1 post-3418 publicacion type-publicacion status-publish hentry category-publicaciones-cientificas-de\" data-id=\"3418\">\n\t\t<div class=\"w-grid-item-h\">\n\t\t\t\t\t\t<div class=\"w-hwrapper usg_hwrapper_2 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_1 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_1 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/Pro-Inflammatory-Cytokines-at-Ultra-Low-Dose-Exert-Anti-Inflammatory-Effect-In-Vitro.pdf\" target=\"_blank\" rel=\"noopener nofollow\">Pro-Inflamatory Cytokines at Ultra-Low Dose Exert Anti-Inflammatory Effect In Vitro: A Possible Mode of Action Involving Sub-Micron Particles?<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_1 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_1 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">Dose Response Journal<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_2 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Floris, I., Rose, T., Collado, J.A., Appel, K., Roesch, C., Lejeune, B.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_5 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2020<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_1\"><p style=\"text-align: justify;\">Tumor necrosis factor-\u03b1 (TNF-\u03b1) and interleukin-1\u03b2 (IL-1\u03b2) are pro-inflammatory cytokines involved in acute and chronic inflammatory diseases. Indeed, immunotherapy blocking these 2 cytokines has been developed. Micro-immunotherapy (MI) also uses ultra-low doses (ULD) of pro-inflammatory cytokines, impregnated on lactose-sucrose pillules, to counteract their overexpression. The study has been conducted with 2 objectives: examine the anti-inflammatory effect in vitro and the capacity of 2 unitary medicines, TNF-\u03b1 (27 CH) and IL-1\u03b2 (27 CH), to reduce the secretion of TNF-\u03b1 in human primary monocytes and THP-1 cells differentiated with phorbol-12-myristate-13-acetate, after lipopolysaccharide (LPS) exposure; then, investigate the presence of particles possibly containing starting materials using tunable resistive pulse sensing technique. The results show that the unitary medicines, tested at 3 pillules concentrations (5.5, 11 and 22 mM), have reduced the secretion of TNF-\u03b1 in both models by about 10\u221220% vs. vehicle control, depending on concentration. In this exploratory study, particles (150\u22121000 nm) have been detected in MI ULD-impregnated pillules and a hypothesis for MI medicines mode of action has been proposed. Conscious that more evaluations are necessary, authors are cautious in the conclusions because the findings described in the study are still limited, and future investigations may lead to different hypothesis.<\/p>\n<\/div><\/div><div class=\"w-vwrapper usg_vwrapper_2 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_1 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/Pro-Inflammatory-Cytokines-at-Ultra-Low-Dose-Exert-Anti-Inflammatory-Effect-In-Vitro.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_2 icon_atleft\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7829609\/\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><div class=\"w-hwrapper usg_hwrapper_3 align_none valign_top\" style=\"--hwrapper-gap:2rem\"><div class=\"w-vwrapper usg_vwrapper_3 align_none valign_top\"><h4 class=\"w-post-elm post_title usg_post_title_2 entry-title\"><a href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/Pro-Inflammatory-Cytokines-at-Ultra-Low-Dose-Exert-Anti-Inflammatory-Effect-In-Vitro.pdf\" target=\"_blank\" rel=\"noopener nofollow\">Pro-Inflamatory Cytokines at Ultra-Low Dose Exert Anti-Inflammatory Effect In Vitro: A Possible Mode of Action Involving Sub-Micron Particles?<\/a><\/h4><div class=\"w-hwrapper usg_hwrapper_4 align_none valign_top wrap\" style=\"--hwrapper-gap:1.4rem\"><div class=\"w-post-elm post_custom_field usg_post_custom_field_3 type_text Revista\"><i class=\"fal fa-book\"><\/i><span class=\"w-post-elm-value\">Dose Response Journal<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_4 type_text autor\"><i class=\"fal fa-users\"><\/i><span class=\"w-post-elm-value\">Floris, I., Rose, T., Collado, J.A., Appel, K., Roesch, C., Lejeune, B.<\/span><\/div><div class=\"w-post-elm post_custom_field usg_post_custom_field_6 type_text date\"><i class=\"fal fa-calendar-alt\"><\/i><span class=\"w-post-elm-value\">2020<\/span><\/div><\/div><div class=\"w-post-elm post_content usg_post_content_2 with_collapsible_content\" data-content-height=\"200px\"><div><p style=\"text-align: justify;\">Tumor necrosis factor-\u03b1 (TNF-\u03b1) and interleukin-1\u03b2 (IL-1\u03b2) are pro-inflammatory cytokines involved in acute and chronic inflammatory diseases. Indeed, immunotherapy blocking these 2 cytokines has been developed. Micro-immunotherapy (MI) also uses ultra-low doses (ULD) of pro-inflammatory cytokines, impregnated on lactose-sucrose pillules, to counteract their overexpression. The study has been conducted with 2 objectives: examine the anti-inflammatory effect in vitro and the capacity of 2 unitary medicines, TNF-\u03b1 (27 CH) and IL-1\u03b2 (27 CH), to reduce the secretion of TNF-\u03b1 in human primary monocytes and THP-1 cells differentiated with phorbol-12-myristate-13-acetate, after lipopolysaccharide (LPS) exposure; then, investigate the presence of particles possibly containing starting materials using tunable resistive pulse sensing technique. The results show that the unitary medicines, tested at 3 pillules concentrations (5.5, 11 and 22 mM), have reduced the secretion of TNF-\u03b1 in both models by about 10\u221220% vs. vehicle control, depending on concentration. In this exploratory study, particles (150\u22121000 nm) have been detected in MI ULD-impregnated pillules and a hypothesis for MI medicines mode of action has been proposed. Conscious that more evaluations are necessary, authors are cautious in the conclusions because the findings described in the study are still limited, and future investigations may lead to different hypothesis.<\/p>\n<\/div><div class=\"toggle-links align_none\"><button class=\"collapsible-content-more\">Read more<\/button><button class=\"collapsible-content-less\">Show less<\/button><\/div><\/div><div class=\"w-vwrapper usg_vwrapper_4 align_none valign_top\"><a class=\"w-btn us-btn-style_1 usg_btn_3 icon_atleft\" href=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2023\/03\/Pro-Inflammatory-Cytokines-at-Ultra-Low-Dose-Exert-Anti-Inflammatory-Effect-In-Vitro.pdf\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-file-pdf\"><\/i><span class=\"w-btn-label\">PDF<\/span><\/a><a class=\"w-btn us-btn-style_1 usg_btn_4 icon_atleft\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7829609\/\" target=\"_blank\" rel=\"noopener nofollow\"><i class=\"fal fa-link\"><\/i><span class=\"w-btn-label\">Link<\/span><\/a><\/div><\/div><\/div>\t\t<\/div>\n\t<\/article>\n<\/div><div class=\"w-grid-preloader\"><div class=\"g-preloader type_custom\">\n\t<div><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"273\" src=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2022\/09\/Symbol_Labo_life_Blue-300x273.png\" class=\"attachment-medium size-medium\" alt=\"\" srcset=\"https:\/\/med.labolife.com\/wp-content\/uploads\/2022\/09\/Symbol_Labo_life_Blue-300x273.png 300w, https:\/\/med.labolife.com\/wp-content\/uploads\/2022\/09\/Symbol_Labo_life_Blue.png 983w, https:\/\/med.labolife.com\/wp-content\/uploads\/2022\/09\/Symbol_Labo_life_Blue-150x136.png 150w, https:\/\/med.labolife.com\/wp-content\/uploads\/2022\/09\/Symbol_Labo_life_Blue-70x64.png 70w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/div>\n<\/div>\n<\/div>\t\t<div class=\"g-loadmore \">\n\t\t\t<div class=\"g-preloader type_1\">\n\t\t\t\t<div><\/div>\n\t\t\t<\/div>\n\t\t\t<button class=\"w-btn us-btn-style_1\">\n\t\t\t\t<span class=\"w-btn-label\">Mehr laden<\/span>\n\t\t\t<\/button>\n\t\t<\/div>\n\t\t\t<div class=\"w-grid-json hidden\" onclick='return {&quot;action&quot;:&quot;us_ajax_grid&quot;,&quot;ajax_url&quot;:&quot;https:\\\/\\\/med.labolife.com\\\/wp-admin\\\/admin-ajax.php&quot;,&quot;infinite_scroll&quot;:true,&quot;max_num_pages&quot;:2,&quot;pagination&quot;:&quot;ajax&quot;,&quot;permalink_url&quot;:&quot;https:\\\/\\\/med.labolife.com\\\/de\\\/wp-json\\\/wp\\\/v2\\\/pages\\\/1471\\\/&quot;,&quot;template_vars&quot;:{&quot;columns&quot;:&quot;1&quot;,&quot;exclude_items&quot;:&quot;none&quot;,&quot;img_size&quot;:&quot;default&quot;,&quot;ignore_items_size&quot;:0,&quot;items_layout&quot;:&quot;2354&quot;,&quot;items_offset&quot;:&quot;1&quot;,&quot;load_animation&quot;:&quot;none&quot;,&quot;overriding_link&quot;:&quot;none&quot;,&quot;post_id&quot;:1471,&quot;query_args&quot;:{&quot;post_type&quot;:[&quot;publicacion&quot;],&quot;tax_query&quot;:[{&quot;taxonomy&quot;:&quot;category&quot;,&quot;field&quot;:&quot;slug&quot;,&quot;terms&quot;:[&quot;publicaciones-cientificas&quot;]}],&quot;post_status&quot;:[&quot;publish&quot;,&quot;acf-disabled&quot;],&quot;posts_per_page&quot;:&quot;20&quot;},&quot;orderby_query_args&quot;:{&quot;orderby&quot;:{&quot;date&quot;:&quot;DESC&quot;}},&quot;type&quot;:&quot;grid&quot;,&quot;us_grid_ajax_index&quot;:1,&quot;us_grid_filter_params&quot;:null,&quot;us_grid_index&quot;:1,&quot;_us_grid_post_type&quot;:&quot;publicacion&quot;,&quot;lang&quot;:&quot;de&quot;}}'><\/div>\n\t<\/div><\/div><\/div><\/div><\/div><\/div><\/section>\n","protected":false},"excerpt":{"rendered":"Tumor necrosis factor-\u03b1 (TNF-\u03b1) and interleukin-1\u03b2 (IL-1\u03b2) are pro-inflammatory cytokines involved in acute and chronic inflammatory diseases. Indeed, immunotherapy blocking these 2 cytokines has been developed. Micro-immunotherapy (MI) also uses ultra-low doses (ULD) of pro-inflammatory cytokines, impregnated on lactose-sucrose pillules, to counteract their overexpression. The study has been conducted with 2 objectives: examine the anti-inflammatory...","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"content-type":"","footnotes":""},"class_list":["post-1471","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/med.labolife.com\/de\/wp-json\/wp\/v2\/pages\/1471","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/med.labolife.com\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/med.labolife.com\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/med.labolife.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/med.labolife.com\/de\/wp-json\/wp\/v2\/comments?post=1471"}],"version-history":[{"count":9,"href":"https:\/\/med.labolife.com\/de\/wp-json\/wp\/v2\/pages\/1471\/revisions"}],"predecessor-version":[{"id":3921,"href":"https:\/\/med.labolife.com\/de\/wp-json\/wp\/v2\/pages\/1471\/revisions\/3921"}],"wp:attachment":[{"href":"https:\/\/med.labolife.com\/de\/wp-json\/wp\/v2\/media?parent=1471"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}